[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 318
1. Xie R, Loose DS, Shipley GL, Xie S, Bassett RL Jr, Broaddus RR: Hypomethylation-induced expression of S100A4 in endometrial carcinoma. Mod Pathol; 2007 Oct;20(10):1045-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We hypothesized that S100A4 would be overexpressed in endometrial carcinoma compared to benign endometrium.
  • Quantitative real-time RT-PCR (qRT-PCR) was used to quantify the mRNA level of S100A4 in benign endometrium (n=19), endometrioid adenocarcinoma (n=87), and non-endometrioid tumors (n=21).
  • S100A4 was overexpressed in the grade 3 endometrioid tumors, uterine papillary serous carcinoma, and uterine malignant mixed müllerian tumor.
  • Expression in grade 1 and grade 2 endometrioid tumors was comparable to that of normal endometrium, which was quite low.
  • Expression was significantly higher in stage III and IV tumors compared with stage I.
  • By immunohistochemistry, S100A4 was expressed in the tumor cell cytoplasm of poorly differentiated tumors, but was not detected in normal endometrial glandular epithelium.
  • In benign endometrium, S100A4 expression was confined to stromal cells.
  • S100A4 was not regulated by estrogen or progesterone, and its expression in tumors was not significantly correlated to estrogen receptor or progesterone receptor content.
  • However, methylation of the S100A4 gene was detected in benign endometrium and grade 1 tumors with low S100A4 expression.
  • In contrast, grade 3 endometrioid tumors with high S100A4 mRNA and protein expression showed no methylation of the gene.
  • [MeSH-minor] Carcinoma, Papillary / genetics. Carcinoma, Papillary / metabolism. Carcinoma, Papillary / pathology. Cell Line, Tumor. Cystadenocarcinoma, Serous / genetics. Cystadenocarcinoma, Serous / metabolism. Cystadenocarcinoma, Serous / pathology. Endometrium / metabolism. Female. Gene Expression. Humans. Immunoenzyme Techniques. Mixed Tumor, Mullerian / genetics. Mixed Tumor, Mullerian / metabolism. Mixed Tumor, Mullerian / pathology. Neoplasm Staging. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17673926.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1P50CA098258-01; United States / NCI NIH HHS / CN / N01-CN-05127
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / S100 Proteins; 142662-27-9 / S100A4 protein, human
  •  go-up   go-down


2. Chen EY, Mehra K, Mehrad M, Ning G, Miron A, Mutter GL, Monte N, Quade BJ, McKeon FD, Yassin Y, Xian W, Crum CP: Secretory cell outgrowth, PAX2 and serous carcinogenesis in the Fallopian tube. J Pathol; 2010 Sep;222(1):110-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The 'p53 signature' is a benign secretory cell outgrowth in the distal Fallopian tube that shares properties with ovarian serous cancer-including p53 mutations-and is a putative serous cancer precursor.
  • SCOUTs are discretely localized alterations commonly containing altered expression of multiple genes within histologically benign tubal epithelium.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 2008 Nov;111(2):226-32 [18718648.001]
  • [Cites] Lancet Oncol. 2008 Dec;9(12):1191-7 [19038766.001]
  • [Cites] Int J Gynecol Cancer. 2009 Jan;19(1):58-64 [19258943.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] Mod Pathol. 2009 Sep;22(9):1243-50 [19525924.001]
  • [Cites] Mod Pathol. 2009 Sep;22(9):1133-8 [19543244.001]
  • [Cites] Int J Gynecol Pathol. 2009 Nov;28(6):570-8 [19851209.001]
  • [Cites] Oncogene. 2010 Feb 25;29(8):1103-13 [19935705.001]
  • [Cites] Mod Pathol. 2010 Oct;23(10):1316-24 [20562848.001]
  • [Cites] Mod Pathol. 2011 Jan;24(1):152-6 [20871594.001]
  • [Cites] J Natl Cancer Inst. 2000 Jun 7;92(11):924-30 [10841828.001]
  • [Cites] J Pathol. 2001 Nov;195(4):451-6 [11745677.001]
  • [Cites] Clin Cancer Res. 2003 Jan;9(1):20-30 [12538447.001]
  • [Cites] Int J Gynecol Pathol. 2003 Apr;22(2):109-20 [12649664.001]
  • [Cites] Science. 1983 Nov 18;222(4625):771-8 [6356358.001]
  • [Cites] N Engl J Med. 1993 Nov 18;329(21):1550-9 [8155119.001]
  • [Cites] Med Pediatr Oncol. 1996 Nov;27(5):440-4 [8827071.001]
  • [Cites] Hum Reprod. 1998 Nov;13(11):3114-20 [9853867.001]
  • [Cites] Mol Cell. 2005 Jun 10;18(6):617-22 [15949437.001]
  • [Cites] Obstet Gynecol. 2005 Dec;106(6):1327-34 [16319259.001]
  • [Cites] Gynecol Oncol. 2006 Jan;100(1):58-64 [16137750.001]
  • [Cites] J Pathol. 2007 Jan;211(1):26-35 [17117391.001]
  • [Cites] Am J Surg Pathol. 2007 Feb;31(2):161-9 [17255760.001]
  • [Cites] J Clin Oncol. 2007 Sep 1;25(25):3985-90 [17761984.001]
  • [Cites] Int J Gynecol Pathol. 2008 Jan;27(1):1-9 [18156967.001]
  • [Cites] J Clin Oncol. 2008 Sep 1;26(25):4160-5 [18757330.001]
  • [Cites] J Clin Oncol. 2008 Nov 10;26(32):5284-93 [18854563.001]
  • (PMID = 20597068.001).
  • [ISSN] 1096-9896
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R21 CA124688-02S1; United States / NCI NIH HHS / CA / P50 CA105009; United States / NIGMS NIH HHS / GM / R01 GM083348; United States / NCI NIH HHS / CA / R21 CA124688; United States / NCI NIH HHS / CA / 1R21CA124688-01A1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / PAX2 Transcription Factor; 0 / PAX2 protein, human; 0 / Tumor Suppressor Protein p53
  • [Other-IDs] NLM/ NIHMS207936; NLM/ PMC2914810
  •  go-up   go-down


3. Medina EA, Arias VL: [Middle ear adenoma]. Biomedica; 2009 Sep;29(3):348-53
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Herein, a middle ear neoplasm is described that became apparent because of its appearance in the external ear duct as it protruded from the middle ear through the eardrum.
  • Following resection, the specimen was determined to be a benign epithelial tumor.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20436986.001).
  • [ISSN] 0120-4157
  • [Journal-full-title] Biomédica : revista del Instituto Nacional de Salud
  • [ISO-abbreviation] Biomedica
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Colombia
  •  go-up   go-down


Advertisement
4. Pereira PD, Lopes CC, Matos AJ, Cortez PP, Gärtner F, Medeiros R, Lopes C: Caveolin-1 in diagnosis and prognosis of canine mammary tumours: comparison of evaluation systems. J Comp Pathol; 2010 Aug-Oct;143(2-3):87-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Caveolin-1 in diagnosis and prognosis of canine mammary tumours: comparison of evaluation systems.
  • Results obtained with both scoring methods were similar, revealing absence of immunoreactivity in normal luminal epithelium and in benign neoplasms and clearly associating Cav-1 expression with malignant transformation.
  • The data suggest that Cav-1 expression is associated with highly malignant subtypes of mammary tumours (i.e. basal-like carcinoma), invasion and metastasis, thus supporting the hypothesis that it may play a major role in the epithelial-mesenchymal transition process.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Carcinoma / veterinary. Caveolin 1 / metabolism. Dog Diseases / diagnosis. Mammary Glands, Animal / metabolism. Mammary Neoplasms, Animal / diagnosis
  • [MeSH-minor] Animals. Caveolae / metabolism. Dogs. Female. Immunohistochemistry. Neoplasm Invasiveness. Neoplasm Metastasis. Prognosis. Research Design. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20153868.001).
  • [ISSN] 1532-3129
  • [Journal-full-title] Journal of comparative pathology
  • [ISO-abbreviation] J. Comp. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Caveolin 1
  •  go-up   go-down


5. Bologna-Molina R, Mosqueda-Taylor A, de Almeida-Oslei P, Toral-Rizo V, Martínez-Mata G: Peripheral desmoplastic ameloblastoma: histopathological and immunohistochemical profile of a case. Med Oral Patol Oral Cir Bucal; 2010 Nov;15(6):e846-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This article reports a new case of this unusual neoplasm in a 66 year-old woman in which the main complaint was an asymptomatic swelling located in the right body of mandible.
  • Histopathological findings were similar to the two previously reported cases of this tumor.
  • Positive immunohistochemical stain for laminin V and type IV collagen suggests an inductive effect of the epithelium over the stroma while the low index of p53 protein and Ki-67 expression in epithelium and stromal cells, as well as CD138 uniform positive-stain in epithelial cells, support the benign biological behavior of this lesion.
  • Including this new case, currently there are only three reports of this rare neoplasm.
  • Reports of new cases of peripheral desmoplastic ameloblastoma are necessary for a better understanding of the origin and behavior of this particular subtype of ameloblastoma.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20526273.001).
  • [ISSN] 1698-6946
  • [Journal-full-title] Medicina oral, patología oral y cirugía bucal
  • [ISO-abbreviation] Med Oral Patol Oral Cir Bucal
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


6. Yuen HF, Chua CW, Chan YP, Wong YC, Wang X, Chan KW: Significance of TWIST and E-cadherin expression in the metastatic progression of prostatic cancer. Histopathology; 2007 Apr;50(5):648-58
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We have previously found that up-regulation of TWIST, a highly conserved basic helix-loop-helix transcription factor, in prostatic cancer cells can promote epithelial to mesenchymal transition through down-regulation of E-cadherin.
  • METHODS AND RESULTS: TWIST and E-cadherin expression was studied in 115 prostatic cancer specimens, eight cases of prostatic intraepithelial neoplasia and 37 cases of benign prostatic hyperplasia by immunohistochemistry.
  • Increased cytoplasmic expression of TWIST was associated with malignant transformation of prostatic epithelium and histological progression of prostatic cancer, while nuclear TWIST expression was significant in predicting the metastatic potential of the primary prostatic cancer.
  • [MeSH-minor] Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Cell Nucleus / metabolism. Cytoplasm / metabolism. Disease Progression. Fluorescent Antibody Technique, Indirect. Humans. Immunoenzyme Techniques. Male. Middle Aged. Neoplasm Metastasis. Prognosis. Tissue Array Analysis. Up-Regulation


7. Sisci D, Morelli C, Garofalo C, Romeo F, Morabito L, Casaburi F, Middea E, Cascio S, Brunelli E, Andò S, Surmacz E: Expression of nuclear insulin receptor substrate 1 in breast cancer. J Clin Pathol; 2007 Jun;60(6):633-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIMS: To assess whether nuclear IRS-1 is present in breast cancer and non-cancer mammary epithelium, and whether it correlates with other markers, especially ERalpha.
  • RESULTS: Median nuclear IRS-1 expression was found to be low in normal mammary epithelial cells (1.6%) and high in benign tumours (20.5%), ductal grade 2 carcinoma (11.0%) and lobular carcinoma (approximately 30%).
  • Median ERalpha expression in normal epithelium, benign tumours, ductal cancer grade 2 and 3, and lobular cancer grade 2 and 3 were 10.5, 20.5, 65.0, 0.0, 80 and 15%, respectively.
  • Nuclear IRS-1 and ERalpha positively correlated in ductal cancer (p<0.001) and benign tumours (p<0.01), but were not associated in lobular cancer and normal mammary epithelium.
  • In ductal carcinoma, both nuclear IRS-1 and ERalpha negatively correlated with tumour grade, size, mitotic index and lymph node involvement.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Breast Neoplasms / metabolism. Cell Nucleus / metabolism. Phosphoproteins / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Ductal, Breast / metabolism. Carcinoma, Ductal, Breast / pathology. Carcinoma, Lobular / metabolism. Carcinoma, Lobular / pathology. Cytoplasm / metabolism. Estrogen Receptor alpha / metabolism. Female. Humans. Immunoenzyme Techniques. Insulin Receptor Substrate Proteins. Mammary Glands, Human / metabolism. Microscopy, Confocal. Middle Aged. Neoplasm Invasiveness. Neoplasm Proteins / metabolism

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2001 Mar 30;276(13):9817-24 [11139588.001]
  • [Cites] J Cell Physiol. 2006 Jan;206(1):35-46 [15965906.001]
  • [Cites] Cancer Res. 2001 Sep 15;61(18):6747-54 [11559546.001]
  • [Cites] Endocr Relat Cancer. 2001 Sep;8(3):197-209 [11566611.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Nov 2;288(3):685-9 [11676497.001]
  • [Cites] J Biol Chem. 2002 May 10;277(19):17231-8 [11877394.001]
  • [Cites] J Biol Chem. 2002 Aug 30;277(35):32078-85 [12063262.001]
  • [Cites] J Cell Physiol. 2003 Feb;194(2):108-16 [12494449.001]
  • [Cites] Oncogene. 2003 Jun 26;22(26):4007-16 [12821935.001]
  • [Cites] Oncogene. 2003 Sep 29;22(42):6589-97 [14528284.001]
  • [Cites] Int J Cancer. 2003 Dec 20;107(6):873-7 [14601044.001]
  • [Cites] Metabolism. 2003 Dec;52(12):1606-11 [14669164.001]
  • [Cites] Horm Metab Res. 2003 Nov-Dec;35(11-12):794-801 [14710360.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jun 22;101(25):9272-6 [15197263.001]
  • [Cites] Oncogene. 2004 Sep 30;23(45):7517-26 [15318176.001]
  • [Cites] J Clin Invest. 1973 Jan;52(1):73-7 [4345203.001]
  • [Cites] Monogr Pathol. 1984;(25):149-74 [6377047.001]
  • [Cites] Bull Cancer. 1989;76(3):311-9 [2544239.001]
  • [Cites] Clin Chem. 1993 Jun;39(6):1345-6 [7684958.001]
  • [Cites] Cancer Res. 1993 Aug 15;53(16):3736-40 [8339284.001]
  • [Cites] Eur J Cancer. 1994;30A(3):307-11 [8204350.001]
  • [Cites] Cancer. 1994 Jul 1;74(1 Suppl):381-400 [8004612.001]
  • [Cites] Trends Biochem Sci. 1994 Jul;19(7):289-93 [8048169.001]
  • [Cites] J Cell Biochem. 2000 Jan;76(4):605-14 [10653980.001]
  • [Cites] J Biol Chem. 2000 Apr 28;275(17):12565-71 [10777546.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2000 Jan;5(1):95-105 [10791772.001]
  • [Cites] Prev Vet Med. 2000 May 30;45(1-2):23-41 [10802332.001]
  • [Cites] Heart. 2000 Jul;84(1):71-8 [10862595.001]
  • [Cites] Int J Cancer. 2000 Nov 20;89(6):506-13 [11102895.001]
  • [Cites] Oncogene. 2000 Nov 20;19(49):5574-81 [11114737.001]
  • [Cites] Breast Cancer Res Treat. 1994;32(1):85-95 [7529598.001]
  • [Cites] Science. 1995 Dec 1;270(5241):1491-4 [7491495.001]
  • [Cites] Endocrinology. 1996 May;137(5):1735-44 [8612509.001]
  • [Cites] EMBO J. 1996 Mar 15;15(6):1292-300 [8635462.001]
  • [Cites] Ann N Y Acad Sci. 1996 Apr 30;784:189-201 [8651569.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 1996;36:615-58 [8725404.001]
  • [Cites] Cancer Res. 1997 Jul 1;57(13):2606-10 [9205064.001]
  • [Cites] Cancer Res. 1997 Aug 1;57(15):3079-83 [9242428.001]
  • [Cites] Diabetologia. 1997 Jul;40 Suppl 2:S2-17 [9248696.001]
  • [Cites] Int J Cancer. 1997 Sep 4;72(5):828-34 [9311601.001]
  • [Cites] J Pathol. 1997 Dec;183(4):412-7 [9496257.001]
  • [Cites] Breast Cancer Res Treat. 1998 Feb;47(3):295-302 [9516083.001]
  • [Cites] Recent Prog Horm Res. 1998;53:119-38 [9769706.001]
  • [Cites] Clin Cancer Res. 1995 Nov;1(11):1429-36 [9815941.001]
  • [Cites] Clin Cancer Res. 1996 Dec;2(12):2037-42 [9816164.001]
  • [Cites] Clin Cancer Res. 1997 Jan;3(1):103-9 [9815544.001]
  • [Cites] Biochem Biophys Res Commun. 1998 Dec 18;253(2):315-9 [9878535.001]
  • [Cites] Recent Results Cancer Res. 1998;152:63-70 [9928547.001]
  • [Cites] Int J Cancer. 1999 Apr 12;81(2):299-304 [10188734.001]
  • [Cites] Mol Endocrinol. 1999 May;13(5):787-96 [10319328.001]
  • [Cites] J Exp Clin Cancer Res. 2004 Sep;23(3):385-94 [15595626.001]
  • [Cites] J Clin Pathol. 2005 Jun;58(6):645-9 [15917419.001]
  • [Cites] J Biol Chem. 2005 Aug 19;280(33):29912-20 [15967802.001]
  • [Cites] Clin Cancer Res. 2001 Aug;7(8):2545-54 [11489838.001]
  • (PMID = 16882697.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Estrogen Receptor alpha; 0 / IRS1 protein, human; 0 / Insulin Receptor Substrate Proteins; 0 / Neoplasm Proteins; 0 / Phosphoproteins
  • [Other-IDs] NLM/ PMC1955087
  •  go-up   go-down


8. Onuma K, Dabbs DJ, Bhargava R: Mammaglobin expression in the female genital tract: immunohistochemical analysis in benign and neoplastic endocervix and endometrium. Int J Gynecol Pathol; 2008 Jul;27(3):418-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mammaglobin expression in the female genital tract: immunohistochemical analysis in benign and neoplastic endocervix and endometrium.
  • Endocervical adenocarcinoma in situ (AIS) showed either weak (predominantly) or moderate (occasionally) expression in about 40% of the cases in comparison with strong positivity in benign endocervical glandular epithelium.
  • Reduction of MGB staining was seen in transition from benign epithelium to AIS.
  • Most endocervical adenocarcinomas are negative for MGB, in contrast to mostly positive endometrioid endometrial adenocarcinomas, however, MGB expression alone is not specific enough to distinguish these 2 tumor types.
  • MGB expression is altered in neoplastic endocervical epithelium compared with normal, and may indicate its decreased expression in the process of early carcinogenesis.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / biosynthesis. Carcinoma in Situ / metabolism. Neoplasm Proteins / biosynthesis. Uterine Neoplasms / metabolism. Uteroglobin / biosynthesis. Uterus / metabolism

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18580321.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Mammaglobin A; 0 / Neoplasm Proteins; 0 / SCGB2A2 protein, human; 9060-09-7 / Uteroglobin
  •  go-up   go-down


9. Mendrinos S, Nolen JD, Styblo T, Carlson G, Pohl J, Lewis M, Ritchie J: Cytologic findings and protein expression profiles associated with ductal carcinoma of the breast in ductal lavage specimens using surface-enhanced laser desorption and ionization-time of flight mass spectrometry. Cancer; 2005 Jun 25;105(3):178-83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Only 5 of 16 DL specimens (31%) from breasts with biopsy-proven carcinoma contained malignant cells, whereas the remaining samples contained only histiocytes and clusters of benign ductal epithelium.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Ductal / pathology. Neoplasm Proteins / analysis. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization / methods
  • [MeSH-minor] BRCA1 Protein / analysis. BRCA2 Protein / analysis. Biomarkers, Tumor / analysis. Biopsy, Fine-Needle. Case-Control Studies. Cytodiagnosis / methods. Female. Humans. Immunohistochemistry. Nipples / cytology. Sampling Studies. Sensitivity and Specificity. Tissue Culture Techniques

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15822128.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BRCA1 Protein; 0 / BRCA2 Protein; 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins
  •  go-up   go-down


10. Ritwik P, Brannon RB: Peripheral odontogenic fibroma: a clinicopathologic study of 151 cases and review of the literature with special emphasis on recurrence. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2010 Sep;110(3):357-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: The peripheral odontogenic fibroma (POdF) is a rare benign neoplasm of odontogenic origin with limited data on recurrence.
  • RESULTS: POdF should be considered a mixed odontogenic tumor because it is composed of active odontogenic epithelial and ectomesenchymal components.
  • Budding of the basal cell layer of the surface squamous epithelium was associated with higher recurrence (P=.0186); 27 cases with recurrence which exhibited this feature.
  • The presence of calcification in direct apposition to epithelial rests was associated with lower recurrence (P=.0076); 13 cases that did not recur exhibited this feature.
  • Budding of the surface epithelium and calcification in apposition to odontogenic epithelial rests are histologic predictors of recurrence.
  • [MeSH-major] Fibroma / pathology. Jaw Neoplasms / pathology. Neoplasm Recurrence, Local / pathology. Odontogenic Tumors / pathology
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Aged. Aged, 80 and over. Child. Child, Preschool. Follow-Up Studies. Humans. Infant. Infant, Newborn. Logistic Models. Male. Middle Aged. Mixed Tumor, Malignant / pathology. Sex Distribution. Time Factors. Young Adult

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Mosby, Inc. All rights reserved.
  • (PMID = 20674403.001).
  • [ISSN] 1528-395X
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


11. Lee SH, Lee DS, You IY, Jeon WJ, Park SM, Youn SJ, Choi JW, Sung R: [Histopathologic analysis of adenoma and adenoma-related lesions of the gallbladder]. Korean J Gastroenterol; 2010 Feb;55(2):119-26
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Among 1,847 cholecystectomized specimens, 63 specimens from 26 benign adenomas, 9 carcinomas in situ (CIS), and 28 invasive carcinomas were selected.
  • A pathologist reviewed all specimens and selected benign adenomas, CIS in the adenoma, and adenoma residue in invasive carcinomas.
  • Adenomas and adenoma-related lesions were classified according to morphology (tubular, tubulopapillary, and papillary) and the consisting epithelium (biliary, pyloric metaplasia, and intestinal metaplasia).
  • The age and the size of the benign adenomas and carcinomas in the adenoma were also compared.
  • All eight carcinomas arising in the adenoma were well-differentiated solitary tumors.
  • The diameters of the carcinomas in the adenoma were, on average, larger than that of the benign adenomas (1.8 cm vs. 0.9 cm, p=0.01).
  • The patients with carcinomas in the adenoma were, on average, older than those with benign adenomas, although the difference was insignificant (57 years vs. 47 years, p=0.09).
  • The morphology and consisting epithelium did not differ between the benign adenomas and carcinomas in the adenoma.
  • [MeSH-minor] Adult. Age Factors. Aged. Carcinoma / epidemiology. Carcinoma / pathology. Carcinoma / surgery. Cell Transformation, Neoplastic. Cholecystectomy. Cystadenoma / epidemiology. Cystadenoma / pathology. Cystadenoma / surgery. Female. Gallstones / complications. Humans. Male. Middle Aged. Neoplasm Invasiveness

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20168058.001).
  • [ISSN] 2233-6869
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Korea (South)
  •  go-up   go-down


12. Cao D, Polyak K, Halushka MK, Nassar H, Kouprina N, Iacobuzio-Donahue C, Wu X, Sukumar S, Hicks J, De Marzo A, Argani P: Serial analysis of gene expression of lobular carcinoma in situ identifies down regulation of claudin 4 and overexpression of matrix metalloproteinase 9. Breast Cancer Res; 2008;10(5):R91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • By comparing the gene expression profile of LCIS to that of benign breast epithelium and stroma, we identified several genes up and down regulated in LCIS.
  • RESULTS: We identified down regulation of claudin 4 and overexpression of matrix metalloproteinase 9 in LCIS relative to normal breast epithelium and stroma.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pathol. 1999 Oct;189(2):161-8 [10547569.001]
  • [Cites] Histopathology. 2005 May;46(5):551-60 [15842637.001]
  • [Cites] Breast Cancer Res Treat. 2000 Aug;62(3):197-210 [11072784.001]
  • [Cites] Cancer Cell. 2004 Jul;6(1):17-32 [15261139.001]
  • [Cites] JAMA. 1967 Jul 10;201(2):82-6 [6072345.001]
  • [Cites] Mod Pathol. 2005 Jun;18(6):741-51 [15696125.001]
  • [Cites] Cancer Res. 2005 Nov 1;65(21):9603-6 [16266975.001]
  • [Cites] Cancer. 2006 May 15;106(10):2104-12 [16604564.001]
  • [Cites] Adv Anat Pathol. 2006 Jul;13(4):157-65 [16858149.001]
  • [Cites] BMC Cancer. 2006;6:186 [16836752.001]
  • [Cites] Am J Surg Pathol. 2007 Mar;31(3):427-37 [17325485.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2007 Sep;15(3):260-6 [17721269.001]
  • [Cites] Virchows Arch. 2007 Sep;451(3):669-80 [17609977.001]
  • [Cites] Am J Surg Pathol. 2008 Apr;32(4):513-23 [18223478.001]
  • [Cites] Cancer Res. 2008 Jun 15;68(12):4606-13 [18559505.001]
  • [Cites] Cancer Cell. 2008 Jul 8;14(1):5-7 [18598938.001]
  • [Cites] Hum Pathol. 2001 Mar;32(3):292-6 [11274638.001]
  • [Cites] Br J Cancer. 2001 Jun 1;84(11):1488-96 [11384099.001]
  • [Cites] Cancer Res. 2001 Jun 1;61(11):4320-4 [11389052.001]
  • [Cites] Int J Surg Pathol. 2001 Apr;9(2):127-31 [11484500.001]
  • [Cites] Clin Cancer Res. 2001 Dec;7(12):3862-8 [11751476.001]
  • [Cites] Lancet. 2003 Jan 11;361(9352):125-9 [12531579.001]
  • [Cites] Int J Cancer. 2003 Aug 20;106(2):208-15 [12800196.001]
  • [Cites] Am J Pathol. 2003 Aug;163(2):653-61 [12875984.001]
  • [Cites] Int J Cancer. 2003 Dec 20;107(6):970-5 [14601057.001]
  • [Cites] Am J Clin Pathol. 2004 Feb;121(2):226-30 [14983936.001]
  • [Cites] Am J Pathol. 2004 May;164(5):1627-33 [15111309.001]
  • [Cites] Cancer. 2004 Jun 15;100(12):2562-72 [15197797.001]
  • [Cites] Cell. 2004 Jun 25;117(7):927-39 [15210113.001]
  • [Cites] Cancer. 1974 Sep;34(3):554-63 [4853024.001]
  • [Cites] Cancer. 1996 Oct 1;78(7):1403-16 [8839545.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1997 May;6(5):297-301 [9149887.001]
  • [Cites] Br J Cancer. 1997;76(9):1131-3 [9365159.001]
  • [Cites] J Surg Oncol. 1998 Jan;67(1):41-6 [9457256.001]
  • [Cites] J Pathol. 1997 Dec;183(4):404-11 [9496256.001]
  • [Cites] Annu Rev Physiol. 1998;60:121-42 [9558457.001]
  • [Cites] Cancer Res. 1998 Jul 1;58(13):2876-80 [9661905.001]
  • [Cites] Cancer Res. 1998 Oct 15;58(20):4721-7 [9788628.001]
  • [Cites] Histopathology. 1999 Sep;35(3):195-200 [10469210.001]
  • [Cites] Semin Diagn Pathol. 1999 Aug;16(3):209-23 [10490198.001]
  • [Cites] Hum Pathol. 2004 Dec;35(12):1531-6 [15619213.001]
  • [Cites] Oncol Rep. 2005 Feb;13(2):193-9 [15643498.001]
  • [Cites] Breast Cancer Res. 2005;7(2):R296-305 [15743508.001]
  • [Cites] J Clin Oncol. 2000 Mar;18(5):1135-49 [10694567.001]
  • (PMID = 18954444.001).
  • [ISSN] 1465-542X
  • [Journal-full-title] Breast cancer research : BCR
  • [ISO-abbreviation] Breast Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA088843; United States / NCI NIH HHS / CA / P50 CA88843
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CLDN4 protein, human; 0 / Claudin-4; 0 / Membrane Proteins; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm; EC 3.4.24.35 / Matrix Metalloproteinase 9
  • [Other-IDs] NLM/ PMC2614499
  •  go-up   go-down


13. Wang XY, Xu SJ, Li XG: Post-operative implantation metastasis of craniopharyngioma: a case report. J Int Med Res; 2010 Sep-Oct;38(5):1876-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Craniopharyngiomas are histologically benign epithelial tumours arising from squamous epithelial remnants of Rathke's pouch, which have a tendency to invade surrounding structures and recur after apparently complete resection.
  • They represent the most frequent non-glial tumour in children, accounting for approximately 5% of paediatric brain neoplasms.
  • [MeSH-major] Craniopharyngioma / secondary. Neoplasm Recurrence, Local / pathology. Pituitary Neoplasms / pathology

  • Genetic Alliance. consumer health - Craniopharyngioma.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21309505.001).
  • [ISSN] 0300-0605
  • [Journal-full-title] The Journal of international medical research
  • [ISO-abbreviation] J. Int. Med. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


14. Kusafuka K, Ueno T, Kurihara K, Murata T, Yurikusa T, Henmi H, Akane M, Ota Y, Kameya T: Cystadenoma of the palate: immunohistochemistry of mucins. Pathol Int; 2008 Aug;58(8):524-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cystadenoma is a relatively rare benign epithelial tumor of the salivary glands, and described herein is an additional case.
  • Histologically, the tumor was composed of bilayered columnar epithelium with cystic change and partial solid growth of glandular structures with clear cells.
  • The tumor cells had mild cellular atypia, but the tumor lacked papillary growth and a fibrous capsule.
  • Immunohistochemistry was positive for cytokeratins, epithelial membrane antigen, MUC1, MUC4 and MUC6, but negative for myoepithelial markers, MUC2, MUC5AC and MUC5B.
  • [MeSH-minor] Biomarkers, Tumor / analysis. Humans. Immunohistochemistry. Male. Middle Aged

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18705774.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Mucins
  •  go-up   go-down


15. Ryan CJ, Haqq CM, Simko J, Nonaka DF, Chan JM, Weinberg V, Small EJ, Goldfine ID: Expression of insulin-like growth factor-1 receptor in local and metastatic prostate cancer. Urol Oncol; 2007 Mar-Apr;25(2):134-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Despite this targeting, there are conflicting data on the presence of this receptor in human tumor samples, largely because of differences in technique.
  • RESULTS: IGF-1 receptor was expressed in normal prostate epithelium in 6 of 6 patients without cancer and in morphologically normal epithelium adjacent to tumor cells in 21 of 22 patients with cancer studied.
  • IGF-1 receptor was present in the prostate tumor epithelium of 28 of 28 primary tumors, 3 of 5 locally recurrent androgen-independent tumors, and in 4 of 5 metastatic lymph nodes.
  • Stromal staining patterns were positive in 2 of 28 specimens near benign epithelium compared to 19 of 30 specimens of stroma surrounding tumor epithelium (P < 0.0001, Fisher exact test).
  • Stroma adjacent to Gleason grade >or=7 tumors showed higher intensity staining than that adjacent to lower grade tumors (P < 0.001).
  • Expression of the closely related insulin receptor did not show expression in either normal or cancer epithelium, or in adjacent stroma.
  • [MeSH-major] Neoplasm Recurrence, Local / metabolism. Neoplasms, Hormone-Dependent / metabolism. Prostatic Neoplasms / metabolism. Receptor, IGF Type 1 / metabolism
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Aged. Aged, 80 and over. Biomarkers, Tumor. Epithelium / metabolism. Epithelium / pathology. Humans. Lymph Nodes. Lymphatic Metastasis / pathology. Male. Middle Aged. Neoplasm Staging. Prognosis. Prostate / metabolism. Prostate / pathology. Receptor, Insulin / metabolism. Receptors, Androgen / metabolism. Stromal Cells / metabolism

  • Genetic Alliance. consumer health - Prostate cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17349528.001).
  • [ISSN] 1078-1439
  • [Journal-full-title] Urologic oncology
  • [ISO-abbreviation] Urol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / K23 CA115775-01; United States / NCI NIH HHS / CA / P50 CA89520; United States / NCI NIH HHS / CA / R01 CA101042-01
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, Androgen; EC 2.7.10.1 / Receptor, IGF Type 1; EC 2.7.10.1 / Receptor, Insulin
  •  go-up   go-down


16. De Sousa Damião R, Fujiyama Oshima CT, Stávale JN, Gonçalves WJ: Analysis of the expression of estrogen receptor, progesterone receptor and chicken ovalbumin upstream promoter-transcription factor I in ovarian epithelial cancers and normal ovaries. Oncol Rep; 2007 Jul;18(1):25-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of the expression of estrogen receptor, progesterone receptor and chicken ovalbumin upstream promoter-transcription factor I in ovarian epithelial cancers and normal ovaries.
  • In the ovary, this role is not clearly defined, with epithelial cancers being poorly responsive to hormone therapy.
  • To investigate the role of these receptors in ovarian carcinogenesis and their implications for cancer prognosis, we evaluated the immunohistochemical expression of ER, progesterone receptor (PR) and COUP-TFI in benign and malignant ovarian epithelial neoplasms and in normal ovaries.
  • A total of 113 ovarian specimens, including 40 diagnosed as malignant epithelial neoplasms (group A), 45 as benign epithelial tumors (group B), and 28 from normal ovaries (group C) were analyzed.
  • Multivariate analysis revealed a residual tumor <1 cm as the most significant clinical prognostic factor in group A (p=0.010, OR=4.14).
  • [MeSH-major] COUP Transcription Factor I / metabolism. Neoplasms, Glandular and Epithelial / metabolism. Ovarian Neoplasms / metabolism. Ovary / metabolism. Receptors, Estrogen / metabolism. Receptors, Progesterone / metabolism

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17549341.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / COUP Transcription Factor I; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone
  •  go-up   go-down


17. Fukunaga N, Ishikawa M, Minato T, Yamamura Y, Ishikura H, Ichimori T, Kimura S, Sakata A, Fujii Y: Lymphoepithelial cyst of the pancreas that was difficult to distinguish from branch duct-type intraductal papillary mucinous neoplasm: report of a case. Surg Today; 2009;39(10):901-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphoepithelial cyst of the pancreas that was difficult to distinguish from branch duct-type intraductal papillary mucinous neoplasm: report of a case.
  • The tumor markers, including DUPAN 2, SPAN-1, and carbohydrate antigen 19-9, were within the normal ranges.
  • Based on these findings, we suspected a branch duct type intraductal papillary mucinous neoplasm.
  • Pathologically, the cyst wall was lined with squamous epithelium surrounded by abundant lymphoid tissue with follicles, consistent with a lymphoepithelial cyst of the pancreas, which is an unusual benign cyst.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Comput Assist Tomogr. 1995 Mar-Apr;19(2):221-4 [7890845.001]
  • [Cites] Pathologe. 1985 Jul;6(4):217-9 [4048076.001]
  • [Cites] Am J Surg. 1995 Jul;170(1):27-32 [7793490.001]
  • [Cites] J Gastrointest Surg. 2004 Mar-Apr;8(3):342-5 [15019932.001]
  • [Cites] Semin Diagn Pathol. 2000 Feb;17(1):56-65 [10721807.001]
  • [Cites] Abdom Imaging. 1998 Mar-Apr;23 (2):185-7 [9516512.001]
  • [Cites] Am J Surg Pathol. 1987 Nov;11(11):899-903 [3674287.001]
  • [Cites] Surg Today. 2008;38(1):68-71 [18085369.001]
  • [Cites] JOP. 2008 Jan 08;9(1):46-9 [18182743.001]
  • [Cites] JOP. 2008 Mar 08;9(2):230-4 [18326936.001]
  • [Cites] Cancer. 2006 Dec 25;108(6):501-6 [17063496.001]
  • (PMID = 19784732.001).
  • [ISSN] 1436-2813
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


18. Shields JA, Eagle RC Jr, Shields CL, Brown GC, Lally SE: Malignant transformation of congenital hypertrophy of the retinal pigment epithelium. Ophthalmology; 2009 Nov;116(11):2213-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant transformation of congenital hypertrophy of the retinal pigment epithelium.
  • PURPOSE: To report a clinicopathologic correlation of an adenocarcinoma that arose from solitary congenital hypertrophy of the retinal pigment epithelium (CHRPE).
  • It had features typical of CHRPE, but there was a small elevated nodule within the flat component, and the diagnosis was adenoma of the retinal pigment epithelium (RPE) arising from CHRPE.
  • Ultrasonography revealed a total retinal detachment and a pedunculated tumor measuring 7.5 mm in thickness.
  • RESULTS: Histopathologically, the mass was composed of a proliferation of atypical RPE cells with a marked infiltration of benign plasma cells.
  • Typical features of CHRPE were present at the base of the tumor.
  • CONCLUSIONS: Congenital hypertrophy of the retinal pigment epithelium, once considered to be a benign and stationary lesion, may spawn a malignant neoplasm.
  • [MeSH-major] Adenocarcinoma / pathology. Cell Transformation, Neoplastic / pathology. Retinal Neoplasms / pathology. Retinal Pigment Epithelium / pathology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19744732.001).
  • [ISSN] 1549-4713
  • [Journal-full-title] Ophthalmology
  • [ISO-abbreviation] Ophthalmology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


19. de Moura JP Jr, Nicolau SM, Stávale JN, da Silva Pinhal MA, de Matos LL, Baracat EC, de Lima GR: Heparanase-2 expression in normal ovarian epithelium and in benign and malignant ovarian tumors. Int J Gynecol Cancer; 2009 Dec;19(9):1494-500
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Heparanase-2 expression in normal ovarian epithelium and in benign and malignant ovarian tumors.
  • Several papers have associated the expression of heparanase 1 with various malignant tumors.
  • OBJECTIVE: The aim of this study was to evaluate the expression of heparanase 2 in epithelial neoplasia of the ovaries and in samples of normal ovarian tissue.
  • METHODS: Seventy-five ovary specimens were analyzed and divided into 3 groups: 23 malignant and 35 benign epithelial ovarian neoplasia and 17 without ovarian disease.
  • RESULTS: In the quantitative analysis, we found positivity indices for heparanase 2 expression of 72.2% and 87.3% in the samples of benign and malignant neoplasias, respectively.
  • In these, the intensity of expression and the expression index were 147.2 and 121.2, respectively, for the benign neoplasia and 134.1 and 118.0 for the malignant neoplasia.
  • Qualitatively, its expression was strong or moderate in 44.2% of the benign and 78.2% of the malignant tumors; its expression in all of the nonneoplastic samples was negative, with the exception of one that was weakly positive.
  • Furthermore, there was no difference in its expression between benign and malignant ovarian epithelial neoplasia.
  • [MeSH-major] Carcinoma / metabolism. Epithelium / metabolism. Glucuronidase / metabolism. Ovarian Neoplasms / metabolism. Ovary / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Cell Proliferation. Cell Transformation, Neoplastic / metabolism. Disease Progression. Female. Humans. Middle Aged. Neoplasm Staging. Young Adult

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • SciCrunch. OMIM: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19955924.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.2.1.- / heparanase; EC 3.2.1.31 / Glucuronidase
  •  go-up   go-down


20. Nykopp TK, Rilla K, Sironen R, Tammi MI, Tammi RH, Hämäläinen K, Heikkinen AM, Komulainen M, Kosma VM, Anttila M: Expression of hyaluronan synthases (HAS1-3) and hyaluronidases (HYAL1-2) in serous ovarian carcinomas: inverse correlation between HYAL1 and hyaluronan content. BMC Cancer; 2009;9:143
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Hyaluronan, a tumor promoting extracellular matrix polysaccharide, is elevated in malignant epithelial ovarian tumors, and associates with an unfavorable prognosis.
  • METHODS: Normal ovaries (n = 5) and 34 serous epithelial ovarian tumors, divided into 4 groups: malignant grades 1+2 (n = 10); malignant grade 3 (n = 10); borderline (n = 4) and benign epithelial tumors (n = 10), were analyzed for mRNA by real-time RT-PCR and compared to hyaluronidase activity, hyaluronan staining, and HAS1-3 immunoreactivity in tissue sections of the same specimens.
  • CONCLUSION: The results indicate that in serous epithelial ovarian malignancies HAS expression is not consistently elevated but HYAL1 expression is significantly reduced and correlates with the accumulation of hyaluronan. (233 words).

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. HYALURONIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Pathol. 2009 Mar;174(3):1027-36 [19218337.001]
  • [Cites] Matrix Biol. 2008 Oct;27(8):653-60 [18762256.001]
  • [Cites] J Biol Chem. 2001 Feb 2;276(5):3361-70 [11058590.001]
  • [Cites] J Biol Chem. 2001 Sep 14;276(37):35111-22 [11451952.001]
  • [Cites] Matrix Biol. 2001 Dec;20(8):499-508 [11731267.001]
  • [Cites] Matrix Biol. 2001 Dec;20(8):509-14 [11731268.001]
  • [Cites] J Biol Chem. 2002 Feb 15;277(7):4593-6 [11717318.001]
  • [Cites] J Biol Chem. 2002 Oct 11;277(41):38013-20 [12145277.001]
  • [Cites] Int J Cancer. 2002 Nov 20;102(3):212-9 [12397638.001]
  • [Cites] Cancer Res. 2002 Nov 15;62(22):6410-3 [12438225.001]
  • [Cites] Int J Cancer. 2003 Nov 10;107(3):359-64 [14506734.001]
  • [Cites] Clin Cancer Res. 2003 Nov 1;9(14):5318-24 [14614016.001]
  • [Cites] Int J Cancer. 2004 Mar 20;109(2):247-52 [14750176.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jul 23;93(15):7832-7 [8755562.001]
  • [Cites] Cancer Res. 1997 Apr 1;57(7):1228-32 [9102203.001]
  • [Cites] J Biol Chem. 1997 May 30;272(22):13997-4000 [9206724.001]
  • [Cites] Int J Cancer. 1997 Nov 4;73(3):327-31 [9359477.001]
  • [Cites] Lab Invest. 1998 Aug;78(8):987-1003 [9714186.001]
  • [Cites] Int J Cancer. 2005 Jan 10;113(2):207-12 [15386412.001]
  • [Cites] Carcinogenesis. 2005 Jan;26(1):65-72 [15358636.001]
  • [Cites] Lab Invest. 2005 Jan;85(1):154-9 [15543203.001]
  • [Cites] Cancer Res. 2005 Mar 15;65(6):2243-50 [15781637.001]
  • [Cites] Int J Oncol. 2005 Jun;26(6):1681-9 [15870886.001]
  • [Cites] Pathol Biol (Paris). 2005 Sep;53(7):372-82 [16085113.001]
  • [Cites] Arkh Patol. 2005;Suppl:1-64 [16108150.001]
  • [Cites] Cancer Res. 2005 Sep 1;65(17):7782-9 [16140946.001]
  • [Cites] Cancer Res. 2008 Jan 15;68(2):483-91 [18199543.001]
  • [Cites] Glycobiology. 2008 Apr;18(4):280-9 [18234732.001]
  • [Cites] Cancer Res. 2000 Jan 1;60(1):150-5 [10646867.001]
  • (PMID = 19435493.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 9004-61-9 / Hyaluronic Acid; EC 2.4.1.17 / Glucuronosyltransferase; EC 2.4.1.212 / hyaluronan synthase; EC 3.2.1.35 / Hyaluronoglucosaminidase
  • [Other-IDs] NLM/ PMC2689240
  •  go-up   go-down


21. Kumar SR, Masood R, Spannuth WA, Singh J, Scehnet J, Kleiber G, Jennings N, Deavers M, Krasnoperov V, Dubeau L, Weaver FA, Sood AK, Gill PS: The receptor tyrosine kinase EphB4 is overexpressed in ovarian cancer, provides survival signals and predicts poor outcome. Br J Cancer; 2007 Apr 10;96(7):1083-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • EphB4 expression was largely absent in normal ovarian surface epithelium, but was expressed in 86% of ovarian cancers.
  • We also studied the biological significance of EphB4 expression in ovarian tumour cells lines in vitro and in vivo.
  • All five malignant ovarian tumour cell lines tested expressed higher levels of EphB4 compared with the two benign cell lines.
  • Treatment of malignant, but not benign, ovarian tumour cell lines with progesterone, but not oestrogen, led to a 90% reduction in EphB4 levels that was associated with 50% reduction in cell survival.
  • Inhibition of EphB4 expression by specific siRNA or antisense oligonucleotides significantly inhibited tumour cell viability by inducing apoptosis via activation of caspase-8, and also inhibited tumour cell invasion and migration.
  • Furthermore, EphB4 antisense significantly inhibited growth of ovarian tumour xenografts and tumour microvasculature in vivo.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. PROGESTERONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dev Biol. 2001 Feb 15;230(2):139-50 [11161568.001]
  • [Cites] Br J Cancer. 2007 Jan 15;96(1):151-6 [17179984.001]
  • [Cites] Ann Oncol. 2003 Feb;14(2):220-6 [12562648.001]
  • [Cites] Int J Cancer. 2003 May 1;104(5):603-10 [12594815.001]
  • [Cites] Pathol Oncol Res. 2004;10(1):26-33 [15029258.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Apr 13;101(15):5583-8 [15067119.001]
  • [Cites] Cell. 1998 May 29;93(5):741-53 [9630219.001]
  • [Cites] Virchows Arch. 1998 Aug;433(2):103-11 [9737787.001]
  • [Cites] Mol Cell. 1999 Sep;4(3):403-14 [10518221.001]
  • [Cites] Cancer Res. 2005 Jun 1;65(11):4623-32 [15930280.001]
  • [Cites] BMC Cancer. 2005;5:119 [16171530.001]
  • [Cites] Oncogene. 2006 Feb 2;25(5):769-80 [16205642.001]
  • [Cites] Panminerva Med. 2006 Mar;48(1):13-7 [16633327.001]
  • [Cites] Gynecol Oncol. 2006 Jul;102(1):15-21 [16499955.001]
  • [Cites] Am J Pathol. 2006 Jul;169(1):279-93 [16816380.001]
  • [Cites] Int J Cancer. 2006 Sep 15;119(6):1236-48 [16615113.001]
  • [Cites] J Cell Sci. 2002 Jan 1;115(Pt 1):25-37 [11801721.001]
  • (PMID = 17353927.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA083639; United States / NCI NIH HHS / CA / R01 CA079218; United States / NCI NIH HHS / CA / R01CA79218
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Progestins; 0 / RNA, Small Interfering; 4G7DS2Q64Y / Progesterone; EC 2.7.10.1 / Receptor, EphB4; EC 3.4.22.- / Caspases
  • [Other-IDs] NLM/ PMC2360128
  •  go-up   go-down


22. Angiero F, Crippa R, Stefani M: Granular cells tumour in the oral cavity: report of eleven cases treated with laser surgery. Minerva Stomatol; 2006 Jul-Aug;55(7-8):423-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Granular cells tumour in the oral cavity: report of eleven cases treated with laser surgery.
  • AIM: The aim of this paper is to examine the clinical and histological feature of oral tumours of neural derivation and discuss their treatment.
  • METHODS: Between 1999 and 2004, 11 patients (6 females, 5 males; age range 28-66 years) were treated for tumours classified as being of neural origin; they were all myoblastomas or granular cells tumours (ex Abrikossoff tumour).
  • RESULTS: During follow-up, which ranged from 5 months to 5 years, there was no indication of tumour recurrence.
  • Histopathological analysis of haematoxylin and eosinstained sections showed all specimens to exhibit features typical of GCT; 6 tumours were well circumscribed, whereas 5 infiltrated adjacent connective tissue, muscle fibres and nerve bundles.
  • Pseudo-epitheliomatous hyperplasia of different degrees was present in 5 patients, along the overlying epithelium.
  • CONCLUSIONS: Granular cell tumour is a benign neoplasm with a tendency to relapse if not completely removed.
  • The usefulness of laser in the surgical treatment of these tumours particularly if small in size, is underlined.
  • [MeSH-major] Granular Cell Tumor / surgery. Laser Therapy. Mouth Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17041542.001).
  • [ISSN] 0026-4970
  • [Journal-full-title] Minerva stomatologica
  • [ISO-abbreviation] Minerva Stomatol
  • [Language] eng; ita
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


23. Guttery DS, Hancox RA, Mulligan KT, Hughes S, Lambe SM, Pringle JH, Walker RA, Jones JL, Shaw JA: Association of invasion-promoting tenascin-C additional domains with breast cancers in young women. Breast Cancer Res; 2010;12(4):R57
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Tenascin-C (TNC) is a large extracellular matrix glycoprotein that shows prominent stromal expression in many solid tumours.
  • The profile of isoforms expressed differs between cancers and normal breast, with the two additional domains AD1 and AD2 considered to be tumour associated.
  • The aim of the present study was to investigate expression of AD1 and AD2 in normal, benign and malignant breast tissue to determine their relationship with tumour characteristics and to perform in vitro functional assays to investigate the role of AD1 in tumour cell invasion and growth.
  • METHODS: Expression of AD1 and AD2 was related to hypoxanthine phosphoribosyltransferase 1 as a housekeeping gene in breast tissue using quantitative RT-PCR, and the results were related to clinicopathological features of the tumours.
  • Statistical analysis was performed using a nonparametric Mann-Whitney test for comparison of clinicopathological features with levels of TNC expression and using Jonckheere-Terpstra trend analysis for association of expression with tumour grade.
  • AD1 mRNA was localised by in situ hybridisation to tumour epithelial cells, and more predominantly to myoepithelium around associated normal breast ducts.
  • Although not tumour specific, AD1 and AD2 expression was significantly more frequent in carcinomas in younger women (age ≤40 years; P < 0.001) and AD1 expression was also associated with oestrogen receptor-negative and grade 3 tumours (P < 0.05).
  • AD1 was found to be incorporated into a tumour-specific isoform, not detected in normal tissues.
  • Overexpression of the TNC-14/AD1/16 isoform significantly enhanced tumour cell invasion (P < 0.01) and growth (P < 0.01) over base levels.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Invest. 2000 Jan;105(1):21-34 [10619858.001]
  • [Cites] Br J Cancer. 1996 Dec;74(11):1796-800 [8956795.001]
  • [Cites] Matrix Biol. 2000 Dec;19(7):581-96 [11102748.001]
  • [Cites] Lancet. 2001 Jun 23;357(9273):1992-4 [11438127.001]
  • [Cites] Cell Struct Funct. 2001 Jun;26(3):179-87 [11565810.001]
  • [Cites] Int J Cancer. 2002 Mar 10;98(2):205-9 [11857409.001]
  • [Cites] Clin Cancer Res. 2002 Apr;8(4):1152-6 [11948127.001]
  • [Cites] Semin Cancer Biol. 2002 Apr;12(2):97-104 [12027581.001]
  • [Cites] Cancer Res. 2002 Jun 1;62(11):3289-97 [12036947.001]
  • [Cites] Eur J Cancer. 2002 Dec;38(18):2362-70 [12460779.001]
  • [Cites] Am J Pathol. 2003 Jun;162(6):1857-67 [12759243.001]
  • [Cites] Int J Cancer. 2003 Aug 10;106(1):8-16 [12794751.001]
  • [Cites] J Pathol. 2003 Dec;201(4):562-72 [14648659.001]
  • [Cites] Science. 2004 Feb 6;303(5659):775-7 [14764858.001]
  • [Cites] Clin Cancer Res. 2004 Aug 15;10(16):5367-74 [15328174.001]
  • [Cites] Cancer Res. 2004 Oct 15;64(20):7377-85 [15492259.001]
  • [Cites] N Engl J Med. 1986 Aug 28;315(9):559-63 [3736639.001]
  • [Cites] J Cell Biol. 1991 Nov;115(4):1127-36 [1720121.001]
  • [Cites] J Cell Physiol. 1992 Mar;150(3):534-44 [1537883.001]
  • [Cites] Lancet. 1992 Jun 13;339(8807):1483 [1351156.001]
  • [Cites] Cancer Res. 1992 Oct 1;52(19):5190-7 [1382837.001]
  • [Cites] Int J Cancer. 1992 Nov 11;52(5):688-92 [1385335.001]
  • [Cites] Nucleic Acids Res. 1993 Jan 11;21(1):163-8 [7680113.001]
  • [Cites] Lancet. 1993 Apr 24;341(8852):1039-43 [8096955.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Nov 1;90(21):10154-8 [7694284.001]
  • [Cites] Development. 1994 Mar;120(3):637-47 [7512896.001]
  • [Cites] J Cell Biol. 1994 Jul;126(2):539-48 [7518469.001]
  • [Cites] Mol Biol Cell. 1994 Apr;5(4):439-53 [7519905.001]
  • [Cites] FEBS Lett. 1994 Sep 26;352(2):216-8 [7523186.001]
  • [Cites] J Biol Chem. 1995 Apr 14;270(15):8650-4 [7536739.001]
  • [Cites] Cancer. 1996 Jan 1;77(1):97-103 [8630946.001]
  • [Cites] FEBS Lett. 1996 Jul 8;389(3):304-8 [8766721.001]
  • [Cites] Mol Biol Cell. 1996 Jun;7(6):883-92 [8816995.001]
  • [Cites] Br J Cancer. 1996 Oct;74(7):999-1004 [8855965.001]
  • [Cites] Int J Cancer. 1997 Jul 17;72(2):236-40 [9219826.001]
  • [Cites] Differentiation. 1997 Nov;62(2):71-82 [9404002.001]
  • [Cites] J Cell Sci. 1998 Apr;111 ( Pt 8):1095-104 [9512505.001]
  • [Cites] Invest Ophthalmol Vis Sci. 1998 Jun;39(7):1135-42 [9620072.001]
  • [Cites] Br J Cancer. 1998 Dec;78(11):1507-13 [9836485.001]
  • [Cites] Am J Pathol. 1999 May;154(5):1345-52 [10329587.001]
  • [Cites] Int J Cancer. 1999 Aug 12;82(4):477-83 [10404058.001]
  • [Cites] Cell. 1999 Jul 23;98(2):137-46 [10428026.001]
  • [Cites] Mol Biol Cell. 1999 Sep;10(9):2933-43 [10473637.001]
  • [Cites] Clin Cancer Res. 2005 Jun 1;11(11):4003-11 [15930334.001]
  • [Cites] Clin Cancer Res. 2005 Jul 15;11(14):5175-80 [16033833.001]
  • [Cites] Clin Cancer Res. 2006 May 15;12(10):3200-8 [16707621.001]
  • [Cites] JAMA. 2006 Jun 7;295(21):2492-502 [16757721.001]
  • [Cites] Cancer Cell. 2006 Dec;10(6):515-27 [17157791.001]
  • [Cites] Histopathology. 2007 Mar;50(4):434-8 [17448018.001]
  • [Cites] Mol Biol Cell. 2007 Nov;18(11):4615-24 [17855508.001]
  • [Cites] J Biol Chem. 2007 Nov 30;282(48):34929-37 [17901052.001]
  • [Cites] Breast Cancer Res. 2007;9(6):404; author reply 405 [18279542.001]
  • [Cites] Clin Cancer Res. 2008 Mar 1;14(5):1368-76 [18316557.001]
  • [Cites] Cancer Res. 2008 Sep 1;68(17):6942-52 [18757408.001]
  • [Cites] Clin Cancer Res. 2008 Sep 1;14(17):5555-64 [18765548.001]
  • [Cites] Breast Cancer Res. 2009;11(2):R24 [19405959.001]
  • [Cites] J Vis Exp. 2009;(29). pii: 1475. doi: 10.3791/1475 [19620957.001]
  • [Cites] J Pathol. 1999 Dec;189(4):475-80 [10629546.001]
  • (PMID = 20678196.001).
  • [ISSN] 1465-542X
  • [Journal-full-title] Breast cancer research : BCR
  • [ISO-abbreviation] Breast Cancer Res.
  • [Language] ENG
  • [Grant] United Kingdom / Cancer Research UK / / ; United Kingdom / Medical Research Council / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Protein Isoforms; 0 / Tenascin
  • [Other-IDs] NLM/ PMC2949648
  •  go-up   go-down


24. Oxenius I, Vacirca F: [A rare case of fibroepithelial polyp of the proximal urethra in a young woman]. Urologia; 2008 Jul-Sep;75(3):193-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Fibroepithelial polyps are benign epithelial tumours which are rare in adults.
  • We report a case of a twenty-seven-year-old woman, presenting with painless terminal gross haematuria, affected by a neoplasm located in the proximal urethra near the bladder neck.
  • Endoscopic image of the tumour and histopatological details are shown.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21086351.001).
  • [ISSN] 0391-5603
  • [Journal-full-title] Urologia
  • [ISO-abbreviation] Urologia
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Xu J, Zhang S, You C, Wang X, Zhou Q: Microvascular density and vascular endothelial growth factor have little correlation with prognosis of craniopharyngioma. Surg Neurol; 2006;66 Suppl 1:S30-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Craniopharyngioma is histologically a benign epithelial tumor located in the supersellar cistern that often presents aggressive growth and repeated recurrence.
  • METHODS: The cohorts consisted of 32 patients with AE and 31 patients with SP tumor.
  • CONCLUSIONS: Microvascular density and VEGF in craniopharyngioma tissue have no correlation with prognosis of the tumor, which may be explained by the minimal blood circulation in the craniopharyngioma.
  • Adamantine epithelioma showed more tendency to recur than SP.
  • [MeSH-major] Craniopharyngioma / blood supply. Craniopharyngioma / metabolism. Neoplasm Recurrence, Local / etiology. Pituitary Neoplasms / blood supply. Pituitary Neoplasms / metabolism. Vascular Endothelial Growth Factor A / metabolism

  • Genetic Alliance. consumer health - Craniopharyngioma.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16904996.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


26. Jaggi M, Johansson SL, Baker JJ, Smith LM, Galich A, Balaji KC: Aberrant expression of E-cadherin and beta-catenin in human prostate cancer. Urol Oncol; 2005 Nov-Dec;23(6):402-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Benign appearing prostate epithelium was used as an internal control in each specimen.
  • Overall, the expression of E-cadherin and beta-catenin is significantly down regulated in PC compared to surrounding benign appearing prostate, which correlates with increasing Gleason grade.
  • [MeSH-minor] Cell Membrane / metabolism. Cell Membrane / pathology. Cell Nucleus / metabolism. Cell Nucleus / pathology. Humans. Male. Neoplasm Staging

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16301117.001).
  • [ISSN] 1078-1439
  • [Journal-full-title] Urologic oncology
  • [ISO-abbreviation] Urol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cadherins; 0 / beta Catenin
  •  go-up   go-down


27. Tryka E, Skomra D, Klatka J, Gieroba R, Olszański W: [Epithelial cell proliferation in nasal polyps]. Otolaryngol Pol; 2005;59(4):523-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Epithelial cell proliferation in nasal polyps].
  • The fact that nasal polyps formation is connected with increase of the epithelial surface suggests that the dysregulation of epithelial cell proliferation takes part in their pathogenesis.
  • Furthermore, macroscopically nonsuspected nasal polyp, usually benign tissue lesion, occasionally may be misdiagnosed such as neoplasm.
  • Only a few studies have undertaken the subject of cell proliferation in nonneoplastic respiratory epithelium.
  • Based on this findings it seems that increased epithelial cell proliferation and chronic inflammation generate the lesion of the nasal mucosa leading to nasal polyps formation.
  • [MeSH-minor] Cell Proliferation. Epithelial Cells / pathology. Female. Humans. Immunohistochemistry. Inflammation / pathology. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16273855.001).
  • [ISSN] 0030-6657
  • [Journal-full-title] Otolaryngologia polska = The Polish otolaryngology
  • [ISO-abbreviation] Otolaryngol Pol
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Ki-67 Antigen
  •  go-up   go-down


28. Cates JM, Byrd RH, Fohn LE, Tatsas AD, Washington MK, Black CC: Epithelial-mesenchymal transition markers in pancreatic ductal adenocarcinoma. Pancreas; 2009 Jan;38(1):e1-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epithelial-mesenchymal transition markers in pancreatic ductal adenocarcinoma.
  • OBJECTIVES: Expression of transcription factors that mediate epithelial-mesenchymal transition (EMT), such as Twist and Slug, is correlated with poor prognosis in many tumor types.
  • Selected EMT markers were studied in a series of pancreatic ductal adenocarcinomas (PDAs) and benign pancreatic tissues to determine whether expression levels correlated with diagnosis, histologic grade, or patient outcome.
  • RESULTS: Twist and Slug were identified in both the nucleus and cytoplasm of benign pancreatic ductal epithelium, chronic pancreatitis, and PDA.
  • Compared with normal ductal epithelium, nuclear levels of Twist are decreased in PDA.
  • Epithelial-mesenchymal transition marker expression was not associated with N-cadherin expression, patient outcome, or duration of survival.
  • CONCLUSIONS: Decreased expression of nuclear Twist is observed in malignant pancreatic epithelium.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Appl Immunohistochem Mol Morphol. 2008 May;16(3):251-62 [18301244.001]
  • [Cites] Hum Pathol. 2007 Apr;38(4):598-606 [17258791.001]
  • [Cites] J Pathol. 2007 Apr;211(5):507-15 [17299729.001]
  • [Cites] Histopathology. 2007 Apr;50(5):648-58 [17394502.001]
  • [Cites] J Clin Pathol. 2007 May;60(5):510-4 [16822877.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Jul 6;358(3):925-30 [17512904.001]
  • [Cites] Pathology. 2007 Jun;39(3):305-18 [17558857.001]
  • [Cites] J Cell Biochem. 2007 Jul 1;101(4):816-29 [17243120.001]
  • [Cites] J Surg Res. 2007 Aug;141(2):196-203 [17583745.001]
  • [Cites] Semin Oncol. 2007 Aug;34(4):303-10 [17674958.001]
  • [Cites] Clin Cancer Res. 2007 Aug 15;13(16):4769-76 [17699854.001]
  • [Cites] Gene. 2000 Oct 17;257(1):1-12 [11054563.001]
  • [Cites] Cancer Res. 2002 Mar 15;62(6):1613-8 [11912130.001]
  • [Cites] Oncogene. 2002 May 9;21(20):3241-6 [12082640.001]
  • [Cites] Am J Pathol. 2002 Nov;161(5):1881-91 [12414534.001]
  • [Cites] Int J Oncol. 2003 Apr;22(4):891-8 [12632084.001]
  • [Cites] Curr Opin Cell Biol. 2003 Dec;15(6):740-6 [14644200.001]
  • [Cites] J Histochem Cytochem. 2004 Jul;52(7):959-65 [15208362.001]
  • [Cites] Cell. 2004 Jun 25;117(7):927-39 [15210113.001]
  • [Cites] Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):4125-33 [15217949.001]
  • [Cites] J Natl Cancer Inst. 1993 Feb 3;85(3):200-6 [8423624.001]
  • [Cites] Am J Surg Pathol. 2005 Feb;29(2):188-95 [15644775.001]
  • [Cites] Clin Cancer Res. 2005 Feb 1;11(3):1174-80 [15709186.001]
  • [Cites] Gynecol Oncol. 2005 Apr;97(1):155-65 [15790452.001]
  • [Cites] Cancer. 2005 Apr 15;103(8):1631-43 [15742334.001]
  • [Cites] Ann Surg Oncol. 2005 Jun;12(6):488-96 [15864483.001]
  • [Cites] Cancer Res. 2005 Jun 15;65(12):5153-62 [15958559.001]
  • [Cites] Development. 2005 Jul;132(14):3151-61 [15983400.001]
  • [Cites] J Clin Oncol. 2005 Jul 10;23(20):4524-31 [16002843.001]
  • [Cites] Cancer Res. 2005 Jul 15;65(14):5991-5; discussion 5995 [16024595.001]
  • [Cites] Cancer Res. 2005 Jul 15;65(14):5996-6000; discussion 6000-1 [16024596.001]
  • [Cites] Cancer Cell. 2005 Sep;8(3):197-209 [16169465.001]
  • [Cites] Clin Cancer Res. 2005 Nov 15;11(22):8070-8 [16299238.001]
  • [Cites] Hum Pathol. 2006 Apr;37(4):431-8 [16564917.001]
  • [Cites] J Cell Biol. 2006 Mar 27;172(7):973-81 [16567498.001]
  • [Cites] Cancer Res. 2006 Apr 1;66(7):3365-9 [16585154.001]
  • [Cites] Br J Cancer. 2006 Jun 19;94(12):1816-22 [16773075.001]
  • [Cites] J Biol Chem. 2006 Jul 28;281(30):21321-31 [16707493.001]
  • [Cites] Br J Cancer. 2007 Jan 29;96(2):314-20 [17211477.001]
  • [Cites] Int J Cancer. 2007 Apr 15;120(8):1634-40 [17236203.001]
  • (PMID = 18766116.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA095103; United States / NCI NIH HHS / CA / P50 CA095103-10; United States / NCI NIH HHS / CA / P50 CA95103
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Biomarkers, Tumor; 0 / CDH2 protein, human; 0 / Cadherins; 0 / Nuclear Proteins; 0 / TWIST1 protein, human; 0 / Transcription Factors; 0 / Twist Transcription Factor; 0 / snail family transcription factors
  • [Other-IDs] NLM/ NIHMS205920; NLM/ PMC2882851
  •  go-up   go-down


29. Bignami M, Pistochini A, Meloni F, Delehaye E, Castelnuovo P: A rare case of oncocytic Schneiderian papilloma with intradural and intraorbital extension with notes of operative techniques. Rhinology; 2009 Sep;47(3):316-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Epithelial cells of cylindrical cell papilloma are oncocytes, which arise from the sinonasal respiratory epithelium, hence the term Oncocytic Schneiderian papilloma.This is a rare and benign neoplasm of the nose and paranasal sinuses and it should be considered in the work-up of all unilateral nasal polypoid lesions.

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19839258.001).
  • [ISSN] 0300-0729
  • [Journal-full-title] Rhinology
  • [ISO-abbreviation] Rhinology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


30. Mandinova A, Kolev V, Neel V, Hu B, Stonely W, Lieb J, Wu X, Colli C, Han R, Pazin MJ, Ostano P, Dummer R, Brissette JL, Dotto GP: A positive FGFR3/FOXN1 feedback loop underlies benign skin keratosis versus squamous cell carcinoma formation in humans. J Clin Invest; 2009 Oct;119(10):3127-37
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A positive FGFR3/FOXN1 feedback loop underlies benign skin keratosis versus squamous cell carcinoma formation in humans.
  • Seborrheic keratoses (SKs) are common, benign epithelial tumors of the skin that do not, or very rarely, progress into malignancy, for reasons that are not understood.
  • We investigated this by gene expression profiling of human SKs and cutaneous squamous cell carcinomas (SCCs) and found that several genes previously connected with keratinocyte tumor development were similarly modulated in SKs and SCCs, whereas the expression of others differed by only a few fold.
  • Knockdown of FOXN1 expression in primary human keratinocytes cooperated with oncogenic RAS in the induction of SCC-like tumors, whereas increased FOXN1 expression triggered the SCC cells to shift to a benign SK-like tumor phenotype, which included increased FGFR3 expression.
  • Thus,we have uncovered a positive regulatory loop between FGFR3 and FOXN1 that underlies a benign versus malignant skin tumor phenotype.

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genes Dev. 2006 Apr 15;20(8):1028-42 [16618808.001]
  • [Cites] J Clin Invest. 2006 Aug;116(8):2201-2207 [16841094.001]
  • [Cites] J Invest Dermatol. 2006 Nov;126(11):2404-7 [16778799.001]
  • [Cites] Blood. 2006 Nov 15;108(10):3465-71 [16849642.001]
  • [Cites] Oral Oncol. 2007 Jan;43(1):60-6 [16807070.001]
  • [Cites] EMBO J. 2007 Mar 7;26(5):1268-78 [17304214.001]
  • [Cites] Genes Dev. 2007 Mar 1;21(5):562-77 [17344417.001]
  • [Cites] Mol Cell Biol. 2007 May;27(10):3732-42 [17353266.001]
  • [Cites] J Invest Dermatol. 2007 Aug;127(8):1883-5 [17392824.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Aug 14;104(33):13450-4 [17673550.001]
  • [Cites] Cell. 2007 Sep 7;130(5):932-42 [17803914.001]
  • [Cites] Differentiation. 2007 Oct;75(8):694-701 [17459087.001]
  • [Cites] World J Urol. 2007 Dec;25(6):581-93 [17912529.001]
  • [Cites] Clin Cancer Res. 2008 Jan 15;14(2):342-6 [18223206.001]
  • [Cites] Neoplasia. 2008 Jan;10(1):1-7 [18231634.001]
  • [Cites] Curr Urol Rep. 2008 Jan;9(1):55-61 [18366975.001]
  • [Cites] EMBO J. 2008 Apr 23;27(8):1243-54 [18388864.001]
  • [Cites] Nat Cell Biol. 2008 Aug;10(8):902-11 [18604200.001]
  • [Cites] Curr Opin Oncol. 2006 May;18(3):228-33 [16552233.001]
  • [Cites] Adv Dermatol. 1999;14:307-57 [10643503.001]
  • [Cites] J Bone Miner Res. 2000 Jan;15(1):155-65 [10646125.001]
  • [Cites] J Natl Cancer Inst. 2000 May 3;92(9):690-8 [10793105.001]
  • [Cites] N Engl J Med. 2001 Mar 29;344(13):975-83 [11274625.001]
  • [Cites] J Invest Dermatol. 2001 Apr;116(4):506-10 [11286615.001]
  • [Cites] Oncogene. 2001 Apr 30;20(19):2453-64 [11402340.001]
  • [Cites] J Korean Med Sci. 2001 Oct;16(5):619-22 [11641533.001]
  • [Cites] Clin Cancer Res. 2002 Feb;8(2):494-501 [11839669.001]
  • [Cites] J Invest Dermatol. 2002 Feb;118(2):303-9 [11841548.001]
  • [Cites] Cell Signal. 2002 Jul;14(7):585-93 [11955951.001]
  • [Cites] Curr Opin Hematol. 2002 Jul;9(4):288-93 [12042702.001]
  • [Cites] Nat Med. 2002 Oct;8(10):1105-14 [12357246.001]
  • [Cites] Nat Rev Cancer. 2003 Jun;3(6):444-51 [12778134.001]
  • [Cites] Dev Cell. 2003 Jun;4(6):865-77 [12791271.001]
  • [Cites] Blood. 2003 Jul 15;102(2):772-3 [12835230.001]
  • [Cites] CA Cancer J Clin. 2003 Sep-Oct;53(5):292-302 [14570228.001]
  • [Cites] Nat Immunol. 2003 Nov;4(11):1128-35 [14528302.001]
  • [Cites] Am Fam Physician. 2003 Nov 15;68(10):1963-8 [14655805.001]
  • [Cites] Cancer Res. 2004 Jul 1;64(13):4555-62 [15231666.001]
  • [Cites] J Cell Sci. 2004 Aug 15;117(Pt 18):4157-68 [15316080.001]
  • [Cites] Cancer Res. 2004 Sep 1;64(17):6035-40 [15342384.001]
  • [Cites] Cancer Res. 1981 May;41(5):1657-63 [7214336.001]
  • [Cites] Cancer Res. 1985 Mar;45(3):1187-97 [2578876.001]
  • [Cites] Cancer Res. 1993 Oct 1;53(19):4477-80 [8402617.001]
  • [Cites] Mol Carcinog. 1994 Sep;11(1):19-28 [7916986.001]
  • [Cites] Nature. 1994 Nov 3;372(6501):103-7 [7969402.001]
  • [Cites] Genomics. 1995 Aug 10;28(3):549-59 [7490093.001]
  • [Cites] J Biol Chem. 1996 Jun 21;271(25):15292-7 [8663044.001]
  • [Cites] Genes Dev. 1996 Sep 1;10(17):2212-21 [8804315.001]
  • [Cites] Science. 1997 Jan 17;275(5298):400-2 [8994040.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Apr 15;94(8):3842-7 [9108066.001]
  • [Cites] Immunogenetics. 1997;46(6):509-15 [9321431.001]
  • [Cites] Trends Biochem Sci. 1998 Feb;23(2):59-62 [9538690.001]
  • [Cites] J Investig Dermatol Symp Proc. 1996 Apr;1(2):136-42 [9627707.001]
  • [Cites] Med Clin North Am. 1998 Nov;82(6):1285-307, v-vi [9889749.001]
  • [Cites] Genes Dev. 1999 Mar 1;13(5):607-19 [10072388.001]
  • [Cites] Dev Biol. 1999 Apr 15;208(2):362-74 [10191051.001]
  • [Cites] Nature. 1999 Apr 8;398(6727):473-4 [10206641.001]
  • [Cites] Hum Mol Genet. 2005 May 1;14(9):1153-60 [15772091.001]
  • [Cites] J Invest Dermatol. 2005 May;124(5):867-76 [15854024.001]
  • [Cites] Cytokine Growth Factor Rev. 2005 Apr;16(2):107-37 [15863029.001]
  • [Cites] Dev Cell. 2005 May;8(5):665-76 [15866158.001]
  • [ErratumIn] J Clin Invest. 2010 Feb;120(2):6455. Pazin, Mike [corrected to Pazin, Michael J]
  • (PMID = 19729838.001).
  • [ISSN] 1558-8238
  • [Journal-full-title] The Journal of clinical investigation
  • [ISO-abbreviation] J. Clin. Invest.
  • [Language] ENG
  • [Grant] United States / NIAMS NIH HHS / AR / AR39190; United States / NCI NIH HHS / CA / CA16038; United States / NIAMS NIH HHS / AR / R01 AR045284; United States / NIAMS NIH HHS / AR / AR054856; United States / NCI NIH HHS / CA / R01 CA073796; United States / Intramural NIH HHS / / ZIA AG000378-03; United States / NIAMS NIH HHS / AR / AR045284-11A1; United States / NIAMS NIH HHS / AR / R01 AR045284-11A1; United States / NIAMS NIH HHS / AR / R01 AR039190; United States / NIAMS NIH HHS / AR / R01 AR055218-02; United States / NCI NIH HHS / CA / P01 CA016038; United States / NCI NIH HHS / CA / CA73796; United States / NIAMS NIH HHS / AR / AR055218-02; United States / NIAMS NIH HHS / AR / AR045284; United States / NIAMS NIH HHS / AR / R01 AR055218; United States / NIAMS NIH HHS / AR / R01 AR054856
  • [Publication-type] Comparative Study; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Forkhead Transcription Factors; 0 / Whn protein; EC 2.7.10.1 / FGFR3 protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, Fibroblast Growth Factor, Type 3
  •  go-up   go-down


31. Diallo M, Cribier B, Scrivener Y: [Warty dyskeratoma: infundibular histogenesis. Anatomoclinical study of 43 cases]. Ann Dermatol Venereol; 2007 Aug-Sep;134(8-9):633-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The exact origin and classification of warty dyskeratoma in epithelial tumours are still debated.
  • The purpose of this study was to examine the relationship between this tumour and the pilosebaceous follicles.
  • DISCUSSION: Based on the histological and immunohistochemical findings, we proposed the hypothesis of benign epithelial tumour of follicular type, beginning in the pilar infundibulum.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Carcinoma / pathology. Child. Darier Disease / pathology. Epithelium / pathology. Hair Follicle / pathology. Histiocytes / pathology. Humans. Keratin-1 / analysis. Keratin-10 / analysis. Keratin-17 / analysis. Keratin-19 / analysis. Keratin-5 / analysis. Keratoacanthoma / pathology. Lymphocytes / pathology. Middle Aged. Retrospective Studies. Sebaceous Glands / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Warts.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17925685.001).
  • [ISSN] 0151-9638
  • [Journal-full-title] Annales de dermatologie et de venereologie
  • [ISO-abbreviation] Ann Dermatol Venereol
  • [Language] fre
  • [Publication-type] Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Keratin-1; 0 / Keratin-17; 0 / Keratin-19; 0 / Keratin-5; 147785-83-9 / Keratin-10
  •  go-up   go-down


32. Ødegaard E, Staff AC, Kaern J, Flørenes VA, Kopolovic J, Tropé CG, Abeler VM, Reich R, Davidson B: The AP-2gamma transcription factor is upregulated in advanced-stage ovarian carcinoma. Gynecol Oncol; 2006 Mar;100(3):462-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To analyze the expression of the AP-2gamma transcription factor in ovarian borderline tumors, early-stage ovarian carcinoma and advanced-stage ovarian carcinoma, and to evaluate its prognostic role in advanced-stage tumors.
  • METHODS: Sections from 14 normal ovaries, 75 borderline tumors, 22 FIGO stage I invasive ovarian carcinomas, and 306 advanced-stage (FIGO stages II-IV) ovarian carcinomas (42 primary tumors, 62 solid metastases, 202 effusions) were evaluated for expression of the transcription factor AP-2gamma using immunohistochemistry.
  • RESULTS: AP-2gamma was detected in the nucleus of tumor cells in 28/75 (37%) borderline tumors, 13/22 (59%) FIGO stage I carcinomas, and 255/306 (83%) advanced-stage carcinomas (P < 0.001, Chi-square test).
  • Benign ovaries were uniformly negative.
  • CONCLUSIONS: AP-2gamma expression is upregulated in advanced-stage ovarian carcinoma compared to early-stage carcinomas, borderline tumors, and the ovarian surface epithelium, and AP-2gamma is specifically localized to cancer cells in effusions, suggesting a role in tumor progression.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Nucleus / metabolism. Female. Gene Expression Regulation, Neoplastic. Humans. Middle Aged. Neoplasm Staging. Proto-Oncogene Proteins c-kit / metabolism. Up-Regulation

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16216317.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Transcription Factor AP-2; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


33. Wang ZC, Buraimoh A, Iglehart JD, Richardson AL: Genome-wide analysis for loss of heterozygosity in primary and recurrent phyllodes tumor and fibroadenoma of breast using single nucleotide polymorphism arrays. Breast Cancer Res Treat; 2006 Jun;97(3):301-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genome-wide analysis for loss of heterozygosity in primary and recurrent phyllodes tumor and fibroadenoma of breast using single nucleotide polymorphism arrays.
  • Phyllodes tumors of the breast are biphasic stromal and epithelial tumors histologically similar to benign fibroadenomas, but with a neoplastic stromal component.
  • In contrast to fibroadenoma, phyllodes tumors can recur and be locally aggressive or be malignant.
  • This study uses SNP array analysis to present a genome-wide map of loss of heterozygosity (LOH) in a cohort of phyllodes tumors and fibroadenomas.
  • LOH is frequent and sometimes extensive in phyllodes tumors, but is rarely seen in fibroadenomas.
  • There is heterogeneity between phyllodes tumors of different patients and no one LOH marker identifies a majority of these lesions.
  • However, a subset of LOH loci occur in multiple cases of phyllodes tumors and are not found in fibroadenomas.
  • Primary phyllodes tumors and paired recurrences from the same patient share common regions of LOH.
  • Specific LOH loci may be associated with pathologic progression in recurrent phyllodes tumors.
  • In a single case of phyllodes tumor containing a malignant epithelial component the malignant epithelium and stroma partially share an LOH genotype, suggesting a common precursor cell for the biphasic malignant components.
  • [MeSH-major] Breast Neoplasms / genetics. Fibroadenoma / genetics. Loss of Heterozygosity. Neoplasms, Multiple Primary / genetics. Neoplasms, Second Primary / genetics. Oligonucleotide Array Sequence Analysis. Phyllodes Tumor / genetics. Polymorphism, Single Nucleotide
  • [MeSH-minor] Cell Transformation, Neoplastic / genetics. DNA, Neoplasm / genetics. Epithelial Cells / pathology. Female. Gene Expression Profiling. Genome, Human. Humans. Stromal Cells / pathology

  • Genetic Alliance. consumer health - Phyllodes Tumor.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16791486.001).
  • [ISSN] 0167-6806
  • [Journal-full-title] Breast cancer research and treatment
  • [ISO-abbreviation] Breast Cancer Res. Treat.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / NCI P50 CA89393-01
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


34. Augustin T, Vandermeer TJ: Intraductal papillary mucinous neoplasm: a clinicopathologic review. Surg Clin North Am; 2010 Apr;90(2):377-98
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraductal papillary mucinous neoplasm: a clinicopathologic review.
  • Intraductal papillary mucinous neoplasm (IPMN) is an intraductal mucin-producing epithelial neoplasm that arises from the main pancreatic duct (MD-IPMN), secondary branch ducts (BD-IPMN), or both (mixed type; Mix-IPMN).
  • Neoplastic progression from benign adenoma to invasive adenocarcinoma has not been proven but is generally thought to occur.
  • With increasing recognition of IPMN, our understanding of the diagnosis and management of the tumors is evolving.
  • [MeSH-minor] Algorithms. Biopsy, Fine-Needle / methods. Cholangiopancreatography, Endoscopic Retrograde. Diagnostic Imaging. Dilatation, Pathologic. Disease Progression. Endosonography. Epithelium / pathology. Humans. Mucins / metabolism. Neoplasm Invasiveness. Pancreatic Ducts / pathology. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20362793.001).
  • [ISSN] 1558-3171
  • [Journal-full-title] The Surgical clinics of North America
  • [ISO-abbreviation] Surg. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Mucins
  • [Number-of-references] 96
  •  go-up   go-down


35. Thamboo TP, Sim R, Tan SY, Yap WM: Primary retroperitoneal mucinous cystadenocarcinoma in a male patient. J Clin Pathol; 2006 Jun;59(6):655-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The 64-year-old man presented with a large retroperitoneal cystic tumour measuring 24 x 20 x 16 cm3, which was removed intact.
  • Areas ranging from a benign mucinous cyst to borderline mucinous tumour to mucinous cystadenocarcinoma were observed on microscopy.
  • Strong patchy staining for cytokeratins 7 and 20 and strong diffuse staining for MUC2 and MUC5AC core peptides, similar to staining patterns in ovarian mucinous tumours, were shown in the benign and atypical epithelium.
  • The theory of its origin from the mucinous metaplasia of peritoneal (mesothelial) inclusion cysts, rather than from ectopic ovarian tissue or ovarian teratomas, is supported by the occurrence of such a tumour in a male patient.
  • [MeSH-minor] Humans. Keratins / metabolism. Male. Middle Aged. Mucins / metabolism. Neoplasm Proteins / metabolism

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 2000 Jun;31(6):672-7 [10872659.001]
  • [Cites] Arch Pathol Lab Med. 2001 May;125(5):691-4 [11300948.001]
  • [Cites] Surg Today. 2001;31(8):747-50 [11510618.001]
  • [Cites] Int J Gynecol Pathol. 2002 Oct;21(4):391-400 [12352188.001]
  • [Cites] Hinyokika Kiyo. 2003 Mar;49(3):145-7 [12728527.001]
  • [Cites] Gynecol Oncol. 1991 Jul;42(1):64-7 [1717354.001]
  • [Cites] APMIS. 1991 Nov;99(11):1055-7 [1958350.001]
  • [Cites] Acta Cytol. 1994 Mar-Apr;38(2):261-6 [8147222.001]
  • [Cites] Hum Pathol. 1994 Apr;25(4):364-72 [8163269.001]
  • [Cites] Gynecol Oncol. 1994 Nov;55(2):308-12 [7959300.001]
  • [Cites] Virchows Arch. 1994;424(1):53-7 [7981904.001]
  • [Cites] Eur J Surg. 1991 Oct;157(10):621-2 [1687258.001]
  • [Cites] Virchows Arch. 1995;426(6):641-5 [7655747.001]
  • [Cites] Clin Imaging. 1996 Apr-Jun;20(2):129-32 [8744823.001]
  • [Cites] J Pathol. 1997 Aug;182(4):385-91 [9306958.001]
  • (PMID = 16731606.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Mucins; 0 / Neoplasm Proteins; 68238-35-7 / Keratins
  • [Number-of-references] 15
  • [Other-IDs] NLM/ PMC1860402
  •  go-up   go-down


36. McKenney JK, Soslow RA, Longacre TA: Ovarian mature teratomas with mucinous epithelial neoplasms: morphologic heterogeneity and association with pseudomyxoma peritonei. Am J Surg Pathol; 2008 May;32(5):645-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian mature teratomas with mucinous epithelial neoplasms: morphologic heterogeneity and association with pseudomyxoma peritonei.
  • Mucinous epithelial neoplasms arising in association with mature teratomas are a heterogeneous group of tumors, but with the exception of a single recent study, their full histologic spectrum, detailed immunophenotype, and association with classic pseudomyxoma peritonei (PMP) have not been fully studied.
  • The morphologic, immunohistochemical, and clinical features of 42 patients with mucinous epithelial tumors arising in association with mature ovarian teratomas were evaluated.
  • Tumor size ranged from 5.5 to greater than 200 cm.
  • Most teratoma-associated mucinous tumors were unilateral, although 1 patient harbored bilateral mucinous tumors in association with bilateral teratomas.
  • Using the 2003 World Health Organization criteria for ovarian intestinal type mucinous neoplasms, 17 (40%) were classified as mucinous cystadenoma, 16 (38%) as intestinal-type mucinous epithelial neoplasm of low malignant potential (IM-LMP), 4 (10%) as intraepithelial carcinoma (IEC), and 5 (12%) as invasive mucinous carcinoma.
  • Mucinous cystadenomas had a varied epithelial lining consisting of lower gastroenteric, gastric foveolar, or müllerian appearance.
  • A CK7+/CK20-phenotype was rare in these later 3 morphologic groups (6%).
  • Pathologic evaluation of the peritoneum in these 12 cases revealed 6 with acellular mucin alone, 3 with low-grade mucinous epithelium (all 3 with ovarian IM-LMP), and 3 with high-grade mucinous carcinomatosis (all 3 with ovarian mucinous adenocarcinoma).
  • We report that a significant proportion of mucinous tumors associated with mature ovarian teratomas present with clinical PMP, which in most cases is associated with IM-LMP.
  • PMP in this setting may harbor microscopic intra-abdominal low-grade mucinous epithelium that is histologically and immunophenotypically similar to that typically seen in appendiceal-related PMP.
  • Pseudomyxoma ovarii is common in this setting, particularly in tumors with IM-LMP histology, but pseudomyxoma ovarii is not predictive of PMP.
  • Ovarian teratoma-associated benign and IM-LMP mucinous neoplasms with microscopic peritoneal low-grade mucinous epithelium do not seem to be at significant risk for intra-abdominal recurrence, but numbers are few and follow-up is limited.
  • [MeSH-minor] Adolescent. Adult. Aged. Biomarkers, Tumor / metabolism. Female. Humans. Middle Aged. Mucins / metabolism. Neoplasms, Multiple Primary


37. Desjardins L: [Choroidal nevi]. J Fr Ophtalmol; 2010 Feb;33(2):136-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We describe the clinical, angiographic, and echographic aspects of benign choroidal nevi and their differential diagnosis represented mostly by congenital hypertrophy of the pigment epithelium, melanocytoma, and mostly suspicious nevi.
  • [MeSH-minor] Aftercare. Diagnosis, Differential. Fluorescein Angiography. Humans. Melanoma / diagnosis. Neoplasm Staging. Ophthalmoscopy. Prognosis. Risk Factors. Tomography, Optical Coherence

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 Elsevier Masson SAS. All rights reserved.
  • (PMID = 20116886.001).
  • [ISSN] 1773-0597
  • [Journal-full-title] Journal français d'ophtalmologie
  • [ISO-abbreviation] J Fr Ophtalmol
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


38. Jang KY, Kim KS, Hwang SH, Kwon KS, Kim KR, Park HS, Park BH, Chung MJ, Kang MJ, Lee DG, Moon WS: Expression and prognostic significance of SIRT1 in ovarian epithelial tumours. Pathology; 2009;41(4):366-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression and prognostic significance of SIRT1 in ovarian epithelial tumours.
  • Therefore, we investigated the prevalence and the prognostic impact of SIRT1 and p53 expression in ovarian epithelial tumours.
  • METHODS: Immunohistochemical expression of SIRT1 and p53 were evaluated using tissue microarray in 40 cases of benign epithelial tumours, 36 cases of borderline tumours, and 90 cases of malignant tumours.
  • RESULTS: Expression of SIRT1 was significantly increased in malignant epithelial tumours compared to benign and borderline epithelial tumours (p < 0.001).
  • Despite the frequent expression of SIRT1 in malignant ovarian epithelial tumours, serous carcinomas of high FIGO stage showed less frequent SIRT1 expression compared to that of low stage serous carcinomas (p = 0.029).
  • [MeSH-major] Biomarkers, Tumor / analysis. Neoplasms, Glandular and Epithelial / metabolism. Neoplasms, Glandular and Epithelial / pathology. Ovarian Neoplasms / metabolism. Ovarian Neoplasms / pathology. Sirtuins / biosynthesis
  • [MeSH-minor] Female. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Middle Aged. Neoplasm Staging. Prognosis. Sirtuin 1. Tissue Array Analysis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19404850.001).
  • [ISSN] 1465-3931
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.5.1.- / SIRT1 protein, human; EC 3.5.1.- / Sirtuin 1; EC 3.5.1.- / Sirtuins
  •  go-up   go-down


39. Wang H, Rosen DG, Wang H, Fuller GN, Zhang W, Liu J: Insulin-like growth factor-binding protein 2 and 5 are differentially regulated in ovarian cancer of different histologic types. Mod Pathol; 2006 Sep;19(9):1149-56
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We examined IGFBP2 and IGFBP5 expression levels using two tissue microarrays, one containing six normal surface epithelium, six benign serous cysts, 10 serous borderline tumors, eight low-grade, and 20 high-grade serous carcinomas.
  • Each tumor was sampled in duplicate with a 1.0-mm punch core needle.
  • IGFBP2 and IGFBP5 were overexpressed in high-grade serous carcinomas compared to normal surface epithelium, benign serous cysts, serous borderline tumors, or low-grade serous carcinoma.
  • They were differentially expressed in different types of ovarian carcinomas, being more often expressed at high levels in high-grade serous carcinoma, malignant mixed mullerian tumors and undifferentiated carcinoma, and more often expressed at low levels or not at all in clear cell and mucinous carcinomas.
  • [MeSH-minor] Adenocarcinoma, Clear Cell / metabolism. Adenocarcinoma, Clear Cell / mortality. Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / mortality. Adenocarcinoma, Mucinous / pathology. Biomarkers, Tumor / metabolism. Carcinoma, Endometrioid / metabolism. Carcinoma, Endometrioid / mortality. Carcinoma, Endometrioid / pathology. Cystadenocarcinoma, Serous / metabolism. Cystadenocarcinoma, Serous / mortality. Cystadenocarcinoma, Serous / pathology. Female. Fluorescent Antibody Technique, Indirect. Humans. Image Processing, Computer-Assisted. Immunoenzyme Techniques. Neoplasm Staging. Survival Rate. Tissue Array Analysis

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Published online 26 May 2006.
  • (PMID = 16729015.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Insulin-Like Growth Factor Binding Protein 2; 0 / Insulin-Like Growth Factor Binding Protein 5
  •  go-up   go-down


40. Depondt J, Shabana el-H, Walker F, Pibouin L, Lezot F, Berdal A: Nasal inverted papilloma expresses the muscle segment homeobox gene Msx2: possible prognostic implications. Hum Pathol; 2008 Mar;39(3):350-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Nasal inverted papilloma is a rare benign tumor of epithelial origin with aggressive evolution, bone destruction, recurrence, and malignant transformation.
  • The protein expression level was directly and significantly associated with tumor recurrence.
  • [MeSH-major] Biomarkers, Tumor / analysis. DNA-Binding Proteins / biosynthesis. Homeodomain Proteins / biosynthesis. Nose Neoplasms / genetics. Nose Neoplasms / metabolism. Papilloma, Inverted / genetics. Papilloma, Inverted / metabolism
  • [MeSH-minor] Acid Phosphatase / metabolism. Adult. Aged. Female. Gene Expression. Genes, Homeobox / physiology. Humans. Immunohistochemistry. Isoenzymes / metabolism. Male. Middle Aged. Neoplasm Recurrence, Local / genetics. Neoplasm Recurrence, Local / metabolism. Neoplasm Recurrence, Local / pathology. Prognosis. RANK Ligand / biosynthesis. RNA, Messenger / analysis. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18187185.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Homeodomain Proteins; 0 / Isoenzymes; 0 / MSX2 protein; 0 / RANK Ligand; 0 / RNA, Messenger; 0 / TNFSF11 protein, human; EC 3.1.3.- / tartrate-resistant acid phosphatase; EC 3.1.3.2 / Acid Phosphatase
  •  go-up   go-down


41. Jaiswal KR, Morales CP, Feagins LA, Gandia KG, Zhang X, Zhang HY, Hormi-Carver K, Shen Y, Elder F, Ramirez RD, Sarosi GA Jr, Spechler SJ, Souza RF: Characterization of telomerase-immortalized, non-neoplastic, human Barrett's cell line (BAR-T). Dis Esophagus; 2007;20(3):256-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, findings in such transformed cells may not be applicable to the non-neoplastic cells of benign Barrett's esophagus.
  • Human Barrett's epithelial cells were immortalized with the insertion of hTERT (human telomerase reverse transcriptase) using a Cre-lox recombination system.
  • Non-neoplastic Barrett's epithelial cells infected with hTERT (BAR-T cells) have been sustained in culture beyond 200 population doublings.
  • BAR-T cells express differentiation Barrett's epithelial markers, such as villin and cytokeratins 4, 8 and 18, and stain positive for Alcian blue, indicating the presence of mucin-producing cells.
  • BAR-T cells are diploid, have histological differentiation markers characteristic of benign Barrett's epithelium, and also maintain appropriate expression of p21 and p53.

  • COS Scholar Universe. author profiles.
  • Cellosaurus - a cell line knowledge resource. culture/stock collections - Cellosaurus - a cell line knowledge resource .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17509124.001).
  • [ISSN] 1120-8694
  • [Journal-full-title] Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  • [ISO-abbreviation] Dis. Esophagus
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / 5T32DK-07745; United States / NIDDK NIH HHS / DK / DK63621
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neoplasm Proteins; EC 2.7.7.49 / TERT protein, human; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


42. Glen A, Gan CS, Hamdy FC, Eaton CL, Cross SS, Catto JW, Wright PC, Rehman I: iTRAQ-facilitated proteomic analysis of human prostate cancer cells identifies proteins associated with progression. J Proteome Res; 2008 Mar;7(3):897-907
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Differential expression of brain creatine kinase (CKBB), soluble catechol-O-methyltransferase (S-COMT), tumor rejection antigen (gp96), and glucose regulated protein, 78 kDa (grp78), was confirmed by Western blotting or independent 2D-PAGE analysis.
  • The clinical relevance of gp96 was assessed by immunohistochemistry using prostate tissues from benign ( n = 95), malignant ( n = 66), and metastatic cases ( n = 3).
  • Benign epithelium showed absent/weak gp96 expression in the basal cells, in contrast to the moderate/strong expression seen in malignant epithelium.
  • Furthermore, there was a statistically significant difference in the intensity of gp96 expression between benign and malignant cases ( p < 0.0005, Mann-Whitney U).
  • [MeSH-major] Neoplasm Proteins / metabolism. Prostatic Neoplasms / metabolism. Proteomics
  • [MeSH-minor] Cell Line, Tumor. Chromatography, Liquid. Disease Progression. Electrophoresis, Gel, Two-Dimensional. Humans. Immunohistochemistry. Male. Reproducibility of Results. Spectrometry, Mass, Electrospray Ionization / methods


43. Esposito NN, Mohan D, Brufsky A, Lin Y, Kapali M, Dabbs DJ: Phyllodes tumor: a clinicopathologic and immunohistochemical study of 30 cases. Arch Pathol Lab Med; 2006 Oct;130(10):1516-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phyllodes tumor: a clinicopathologic and immunohistochemical study of 30 cases.
  • CONTEXT: Phyllodes tumors (PTs) of the breast are biphasic neoplasms composed of epithelium and a spindle-cell stroma.
  • Currently, PTs are classified as benign, borderline, or malignant based on histopathologic features.
  • However, histologic classification does not always predict outcome.
  • DESIGN: Sixteen benign, 8 borderline, and 6 malignant PTs with follow-up were examined for reactivity across a panel of immunohistochemical stains, including c-Kit, endothelin 1, p16, p21, p53, and Ki-67.
  • Tumor variables were compared among tumor subgroups and between tumors that did and did not recur.
  • RESULTS: Of the 30 PTs, 4 recurred (1 benign, 2 borderline, 1 malignant).
  • One patient with a malignant tumor died of metastatic disease 34 months after initial diagnosis.
  • The overall positive rate of c-Kit immunoreactivity was 13% in benign, 63% in borderline, and 67% in malignant PTs.
  • Endothelin 1 epithelial cytoplasmic staining was seen in 100% of benign, 50% of borderline, and 17% of malignant PTs.
  • Additionally, p16, p21, p53, and Ki-67 were differentially expressed among benign, borderline, and malignant tumors.
  • CONCLUSIONS: Stromal c-Kit positivity and epithelial endothelin 1 negativity are more often associated with malignant PTs; however, only positive margin status is significantly associated with tumor behavior.
  • [MeSH-major] Breast Neoplasms / metabolism. Breast Neoplasms / pathology. Phyllodes Tumor / metabolism. Phyllodes Tumor / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Disease Progression. Endothelin-1 / metabolism. Epithelium / metabolism. Female. Humans. Immunohistochemistry / methods. Ki-67 Antigen / metabolism. Mastectomy. Mastectomy, Segmental. Middle Aged. Neoplasm Recurrence, Local. Prognosis. Proto-Oncogene Proteins c-kit / metabolism. Staining and Labeling. Tumor Suppressor Protein p53 / metabolism

  • Genetic Alliance. consumer health - Phyllodes Tumor.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17090194.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Endothelin-1; 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


44. Layfield LJ, Jarboe EA: Cytopathology of the pancreas: neoplastic and nonneoplastic entities. Ann Diagn Pathol; 2010 Apr;14(2):140-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Interpretation of cytologic material obtained from the pancreas is complex because of the large number of reactive processes and benign and malignant neoplasms arising within the pancreas.
  • The cytologic appearances of a majority of pancreatic neoplasms are characteristic, allowing precise recognition of the type of neoplasm present.
  • Whereas separation of neuroendocrine, acinar, and ductal neoplasms is usually straightforward, the greatest diagnostic challenge in pancreatic fine-needle aspiration is the separation of atypical epithelium secondary to chronic pancreatitis from well-differentiated ductal adenocarcinoma.
  • These noninvasive lesions include pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasm.
  • [MeSH-major] Pancreas / pathology. Pancreatic Diseases / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Diseases.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20227021.001).
  • [ISSN] 1532-8198
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 85
  •  go-up   go-down


45. Acevedo-Henao CM, Talagas M, Marianowski R, Pradier O: Recurrent inverted papilloma with intracranial and temporal fossa involvement: A case report and review of the literature. Cancer Radiother; 2010 Jun;14(3):202-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Inverted papilloma (IP) is a rare nasosinusal benign tumour, with epithelium surface inversion to inside the stroma.
  • As a conclusion, inverted papilloma is a benign tumour with an aggressive course, tendency to recurrence and progression to malignancy.
  • [MeSH-minor] Carcinoma, Squamous Cell / etiology. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / surgery. Combined Modality Therapy. Disease Progression. Ear, Middle / pathology. Facial Paralysis / etiology. Fatal Outcome. Hearing Loss, Conductive / etiology. Humans. Male. Middle Aged. Nasal Obstruction / etiology. Neoplasm Invasiveness / pathology. Neoplasm Recurrence, Local / surgery. Petrous Bone / pathology. Petrous Bone / surgery. Radiotherapy, Conformal. Reoperation. Temporal Lobe / pathology. Temporal Lobe / surgery

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Société française de radiothérapie oncologique (SFRO). Published by Elsevier SAS. All rights reserved.
  • (PMID = 20418144.001).
  • [ISSN] 1769-6658
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 21
  •  go-up   go-down


46. Basile JR, Klene C, Lin YL: Calcifying odontogenic cyst with odontogenic keratocyst: a case report and review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2010 Apr;109(4):e40-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The calcifying odontogenic cyst (COC), first identified as a separate and distinct lesion by Gorlin et al. in 1962, is an uncommon benign lesion, consisting of a proliferation of odontogenic epithelium and scattered nests of ghost cells and calcifications that may form the lining of a cyst or present as a solid mass.
  • The COC occurs alone or occasionally with odontomas or other odontogenic tumors, and it is this variable histology and clinical behavior that has raised the question of whether or not it is a cyst or a true neoplasm.
  • The odontogenic keratocyst (OKC) is a locally aggressive odontogenic cyst lined by parakeratinizing epithelium that also exhibits characteristics of a neoplasm, including rapid growth, a high rate of recurrence when treated conservatively, and the presence of a gene mutation.
  • [MeSH-major] Mandibular Diseases / complications. Maxillary Neoplasms / complications. Odontogenic Cyst, Calcifying / complications. Odontogenic Cysts / complications
  • [MeSH-minor] Adult. Ameloblasts / pathology. Biopsy. Connective Tissue / pathology. Diagnosis, Differential. Epithelium / pathology. Humans. Keratins. Male

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Mosby, Inc. All rights reserved.
  • (PMID = 20303045.001).
  • [ISSN] 1528-395X
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 68238-35-7 / Keratins
  • [Number-of-references] 20
  •  go-up   go-down


47. Wang Q, Zhang P, Zhang Q, Wang X, Li J, Ma C, Sun W, Zhang L: Analysis of CD137 and CD137L expression in human primary tumor tissues. Croat Med J; 2008 Apr;49(2):192-200
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of CD137 and CD137L expression in human primary tumor tissues.
  • AIM: To assess the expression of CD137 and CD137L in human primary tumor tissues and their potential role in tumor immunity.
  • METHODS: Expression of CD137 and CD137L was assessed by immunohistochemistry in frozen sections of 12 human normal tissues, 15 benign tumors of epithelial or mesenchymal origin (adenoma and leiomyoma), and 36 malignant tumors of epithelial origin (squamous cell carcinoma and adenocarcinoma).
  • The expression of CD137L on 9 human tumor cell lines (3 hepatocarcinoma, 2 lung carcinoma, 2 colon carcinoma, 1 lymphoma, and 1 leukemia) was detected by reverse transcription polymerase chain reaction.
  • To analyze the role of CD137L expressed on tumor cells, we co-cultured tumor cells expressing CD137L with activated T lymphocytes expressing CD137 or with Chinese hamster ovary cells expressing CD137 and then detected by ELISA the levels of cytokines (IL-8, IFN-gamma) secreted by tumor cells or activated T cells.
  • RESULTS: The expression of CD137 and CD137L was observed only in human benign (2/15, 3/15) or malignant tumors (15/36, 21/36), but not in normal tissues (0/12, 0/12).
  • CD137 was expressed on the vessel walls within tumor tissues, whereas CD137L was expressed on tumor cells.
  • The expression of CD137 and CD137L was more common in malignant tumors, especially in moderate or low-differentiated tumors.
  • Furthermore, CD137L expression found on tumor cell lines was functional because the ligation of CD137L on lung squamous carcinoma cells L78 with CD137 on T cells induced IFN-gamma production by T cells, and ligation of CD137L on hepatocarcinoma cells HepG2.2.15 with CD137 triggered tumor cells to produce IL-8.
  • CONCLUSION: CD137 and CD137L are expressed in different human primary tumor tissues, suggesting that they may influence the progression of tumors.
  • [MeSH-minor] Cell Line, Tumor. Disease Progression. Humans. Immunohistochemistry. Signal Transduction. Tumor Cells, Cultured

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Immunol Ther Exp (Warsz). 1999;47(5):275-9 [10604232.001]
  • [Cites] J Immunol. 2000 Sep 1;165(5):2903-10 [10946324.001]
  • [Cites] Am J Clin Pathol. 2001 Apr;115(4):543-9 [11293902.001]
  • [Cites] J Immunol. 2001 Aug 1;167(3):1313-24 [11466348.001]
  • [Cites] J Immunol. 2002 May 15;168(10):4897-906 [11994439.001]
  • [Cites] Cancer Res. 2002 Jun 15;62(12):3459-65 [12067989.001]
  • [Cites] Eur J Immunol. 2002 Dec;32(12):3617-27 [12516549.001]
  • [Cites] Cell Immunol. 2003 Nov;226(1):37-44 [14746806.001]
  • [Cites] Transpl Int. 2004 Aug;17(7):351-61 [15349720.001]
  • [Cites] Blood. 1995 Feb 15;85(4):1043-52 [7849293.001]
  • [Cites] J Immunol. 1995 Oct 1;155(7):3360-7 [7561030.001]
  • [Cites] J Immunol. 1998 Mar 1;160(5):2488-94 [9498794.001]
  • [Cites] J Exp Med. 1998 Jun 1;187(11):1849-62 [9607925.001]
  • [Cites] Semin Immunol. 1998 Dec;10(6):481-9 [9826581.001]
  • [Cites] J Leukoc Biol. 2005 Mar;77(3):281-6 [15618293.001]
  • [Cites] Annu Rev Immunol. 2005;23:23-68 [15771565.001]
  • [Cites] Neuro Oncol. 2005 Apr;7(2):122-33 [15831231.001]
  • [Cites] J Immunother. 2005 Sep-Oct;28(5):449-60 [16113601.001]
  • [Cites] Hum Gene Ther. 2006 Aug;17(8):798-806 [16942440.001]
  • [Cites] Clin Cancer Res. 2007 May 1;13(9):2758-67 [17460060.001]
  • [Cites] J Immunol. 2007 Oct 1;179(7):4910-8 [17878391.001]
  • (PMID = 18461674.001).
  • [ISSN] 1332-8166
  • [Journal-full-title] Croatian medical journal
  • [ISO-abbreviation] Croat. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Croatia
  • [Chemical-registry-number] 0 / 4-1BB Ligand; 0 / Antigens, CD137
  • [Other-IDs] NLM/ PMC2359873
  •  go-up   go-down


48. Yang K, Tang Y, Habermehl GK, Iczkowski KA: Stable alterations of CD44 isoform expression in prostate cancer cells decrease invasion and growth and alter ligand binding and chemosensitivity. BMC Cancer; 2010 Jan 14;10:16
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PCa loses expression of CD44 standard (CD44s) that is present in benign epithelium, and overexpresses the novel splice variant isoform, CD44v7-10.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Immunol. 2000 Jan;30(1):245-53 [10602047.001]
  • [Cites] Prostate. 2009 Aug 1;69(11):1151-63 [19399788.001]
  • [Cites] Int J Cancer. 2001 Jan 1;91(1):67-75 [11149422.001]
  • [Cites] Genes Dev. 2001 Apr 15;15(8):968-80 [11316791.001]
  • [Cites] J Biol Chem. 2002 Mar 22;277(12):10531-8 [11792695.001]
  • [Cites] J Pathol. 2002 Jun;197(2):148-54 [12015737.001]
  • [Cites] Cancer Cell. 2002 Sep;2(3):243-7 [12242156.001]
  • [Cites] Genes Dev. 2002 Dec 1;16(23):3074-86 [12464636.001]
  • [Cites] Anticancer Res. 2003 Jul-Aug;23(4):3129-40 [12926045.001]
  • [Cites] Lab Invest. 2004 Jul;84(7):894-907 [15107804.001]
  • [Cites] Nature. 1970 Aug 15;227(5259):680-5 [5432063.001]
  • [Cites] J Biol Chem. 1992 Nov 5;267(31):22073-8 [1429559.001]
  • [Cites] Cancer Res. 1998 Jun 1;58(11):2350-2 [9622073.001]
  • [Cites] J Urol. 1998 Oct;160(4):1562-6 [9751413.001]
  • [Cites] Cancer Res. 1999 Jan 1;59(1):219-26 [9892210.001]
  • [Cites] Anticancer Res. 2005 May-Jun;25(3B):2075-83 [16158948.001]
  • [Cites] Oncol Rep. 2006 Jan;15(1):199-206 [16328056.001]
  • [Cites] Cell Death Differ. 2006 Mar;13(3):465-77 [16167069.001]
  • [Cites] Anticancer Res. 2006 Jul-Aug;26(4B):2863-72 [16886606.001]
  • [Cites] Oncogene. 2007 Feb 8;26(6):836-50 [16953231.001]
  • [Cites] J Cell Biochem. 2007 Mar 1;100(4):1056-69 [17131386.001]
  • [Cites] Oncogene. 2007 Apr 26;26(19):2747-58 [17057731.001]
  • [Cites] Prostate. 2008 Jun 15;68(9):975-84 [18361411.001]
  • [Cites] BMC Cancer. 2008;8:260 [18793421.001]
  • [Cites] Hum Pathol. 2009 Feb;40(2):252-8 [18835619.001]
  • [Cites] Mol Cancer Res. 2009 Feb;7(2):168-79 [19208744.001]
  • [Cites] Prostate. 2009 May 15;69(7):787-98 [19189306.001]
  • [Cites] J Urol. 2000 Dec;164(6):2156-61 [11061947.001]
  • (PMID = 20074368.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / PC / PC060671
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / Antineoplastic Agents; 0 / Ligands; 0 / Protein Isoforms; 0 / Taxoids; 15H5577CQD / docetaxel
  • [Other-IDs] NLM/ PMC2820461
  •  go-up   go-down


49. Zhao H, Davydova L, Mandich D, Cartun RW, Ligato S: S100A4 protein and mesothelin expression in dysplasia and carcinoma of the extrahepatic bile duct. Am J Clin Pathol; 2007 Mar;127(3):374-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We evaluated the expression of S100A4 protein and mesothelin in dysplasia and carcinoma of the extrahepatic bile duct (EBD) and their potential use as adjuncts for differentiating carcinomatous and significant high-grade dysplastic epithelium from reactive or inflammatory glandular atypia of the EBD.
  • We used immunohistochemical analysis on formalin-fixed tissue sections from 10 cases of carcinoma, 6 cases of high-grade dysphasia (HGD), 4 cases of low-grade dysplasia (LGD), and 10 cases of benign or reactive or inflammatory epithelium from the EBD.
  • No case of normal or reactive epithelium was positive for S100A4 protein or mesothelin.
  • S100A4 protein alone or combined with mesothelin can be used as an adjunct in differentiating carcinomatous and significant high-grade dysplastic epithelium from LGD and reactive or inflammatory glandular atypia of the EBD.
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Carcinoma in Situ / metabolism. Carcinoma in Situ / pathology. Epithelium / chemistry. Epithelium / pathology. GPI-Linked Proteins. Humans. Immunohistochemistry. Neoplasm Invasiveness

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17276942.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / S100 Proteins; 0 / mesothelin; 142662-27-9 / S100A4 protein, human
  •  go-up   go-down


50. Rosner IL, Ravindranath L, Furusato B, Chen Y, Gao C, Cullen J, Sesterhenn IA, McLeod DG, Srivastava S, Petrovics G: Higher tumor to benign ratio of the androgen receptor mRNA expression associates with prostate cancer progression after radical prostatectomy. Urology; 2007 Dec;70(6):1225-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Higher tumor to benign ratio of the androgen receptor mRNA expression associates with prostate cancer progression after radical prostatectomy.
  • Because AR mutations or amplification are rare in early stage CaP, we hypothesized that altered AR expression in prostate tumor cells may provide a prognostic indicator of disease progression.
  • METHODS: RNA from laser capture microdissected (LCM) tumor and benign epithelial cells from radical prostatectomy specimens of 115 hormone-naive patients were studied.
  • A ratio of the expression of AR gene, normalized to GAPDH gene expression in the same specimens, was compared in tumor and benign epithelial cells (tumor-to-benign ratio) and correlated with clinicopathologic features.
  • RESULTS: Paired t test analysis revealed a 62% lower AR expression in tumor tissue compared with benign tissue (P = 0.0005).
  • However, multivariate Cox proportional hazards regression analysis of time to PSA recurrence revealed that higher tumor cell associated AR expression (continuous, log-transformed), significantly increases odds of prostate-specific antigen (PSA) recurrence (P = 0.0139) when controlling for age at surgery, race, time from diagnosis to surgery, risk stratification, pathologic T stage, Gleason sum, and margin status.
  • CONCLUSIONS: Quantitative determination of AR gene expression levels in prostate epithelial cells may be useful for predicting PSA recurrence.


51. Kuo YJ, Ho DM, Tsai YF, Hsu CY: Invasive ductal carcinoma arising in phyllodes tumor with isolated tumor cells in sentinel lymph node. J Chin Med Assoc; 2010 Nov;73(11):602-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Invasive ductal carcinoma arising in phyllodes tumor with isolated tumor cells in sentinel lymph node.
  • Phyllodes tumor (PT) consists of stroma of variable grading and benign ductal epithelium.
  • Although exceptional, carcinomas that arise from the epithelium in PTs do exist, and seem to behave less aggressively than the usually encountered breast carcinoma.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / pathology. Lymph Nodes / pathology. Phyllodes Tumor / pathology. Sentinel Lymph Node Biopsy
  • [MeSH-minor] Adult. Female. Humans. Neoplasm Invasiveness

  • Genetic Alliance. consumer health - Phyllodes Tumor.
  • Genetic Alliance. consumer health - invasive ductal carcinoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier. Published by Elsevier B.V. All rights reserved.
  • (PMID = 21093830.001).
  • [ISSN] 1728-7731
  • [Journal-full-title] Journal of the Chinese Medical Association : JCMA
  • [ISO-abbreviation] J Chin Med Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] China (Republic : 1949- )
  •  go-up   go-down


52. Zhang J, Li YL, Zhou CY, Hu YT, Chen HZ: Expression of octamer-4 in serous and mucinous ovarian carcinoma. J Clin Pathol; 2010 Oct;63(10):879-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIMS: To assess the expression of Oct4 in epithelial ovarian tumours.
  • METHODS: Expression of Oct4 was evaluated by immunohistochemistry in 460 cases of various epithelial ovarian lesions as well as 35 cases of normal fallopian tube epithelium.
  • RESULTS: Oct4 expression was significantly increased from normal epithelium (both ovarian epithelium and fallopian tube epithelium) to benign and borderline cystadenoma to carcinoma in the serous lesion subgroup.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / metabolism. Cystadenoma / metabolism. Octamer Transcription Factor-3 / metabolism. Ovarian Neoplasms / metabolism
  • [MeSH-minor] Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. Disease Progression. Epithelium / metabolism. Fallopian Tubes / metabolism. Female. Humans. Neoplasm Proteins / metabolism. Neoplasm Staging. Ovary / metabolism

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20876318.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / Octamer Transcription Factor-3; 0 / POU5F1 protein, human
  •  go-up   go-down


53. Corzo C, Corominas JM, Tusquets I, Salido M, Bellet M, Fabregat X, Serrano S, Solé F: The MYC oncogene in breast cancer progression: from benign epithelium to invasive carcinoma. Cancer Genet Cytogenet; 2006 Mar;165(2):151-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The MYC oncogene in breast cancer progression: from benign epithelium to invasive carcinoma.
  • One hypothesis for breast cancer development suggests that breast carcinogenesis involves a progression of events leading from benign epithelium to hyperplasia (with or without atypia) to carcinoma in situ and then invasive carcinoma.
  • Benign lesions and normal adjacent cells were classified as normal.
  • The presence of MYC amplification only in invasive cells suggests that the finding of MYC amplification could reflect an advanced tumor progression.
  • [MeSH-minor] Chromosomes, Human, Pair 8. Disease Progression. Female. Humans. In Situ Hybridization, Fluorescence. Neoplasm Invasiveness. Paraffin Embedding

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16527609.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


54. Chen XD, Shi HY, Zhang XF: [Clinicopathologic analysis of 102 cases of mixed epithelial and mesenchymal tumors of the uterus]. Zhonghua Fu Chan Ke Za Zhi; 2007 Apr;42(4):219-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinicopathologic analysis of 102 cases of mixed epithelial and mesenchymal tumors of the uterus].
  • OBJECTIVE: To study the clinical and pathologic features, histological criteria and pathologic factors contributing to diagnosis of mixed epithelial and mesenchymal tumors (mixed müllerian tumors, MMT) of the uterus.
  • Benign MMT usually presented as exophytic polypoid masses extending into the uterine cavity or protruding through the external os, often broad-based, lobulated and papillary.
  • It was hard to distinguish low-grade malignant MMT from the benign ones by gross appearance.
  • Histologically, MMT showed a biphasic differentiation of mesenchymal and epithelial components.
  • MMT were classified according to whether these elements were benign or malignant.
  • Recurrent tumors were almost always confined to the original site.
  • CONCLUSIONS: Uterine MMT tumors according to WHO diagnostic criteria are not rare.
  • The recurrent adenofibromas may be a kind of borderline tumors with benign appearances and malignant behavior.
  • [MeSH-major] Mixed Tumor, Mullerian / pathology. Uterine Neoplasms / pathology
  • [MeSH-minor] Adenofibroma / pathology. Adenomyoma / pathology. Adolescent. Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Epithelium / pathology. Female. Humans. Middle Aged. Neoplasm Recurrence, Local. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17631758.001).
  • [ISSN] 0529-567X
  • [Journal-full-title] Zhonghua fu chan ke za zhi
  • [ISO-abbreviation] Zhonghua Fu Chan Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


55. Deshpande V, Mino-Kenudson M, Brugge WR, Pitman MB, Fernandez-del Castillo C, Warshaw AL, Lauwers GY: Endoscopic ultrasound guided fine needle aspiration biopsy of autoimmune pancreatitis: diagnostic criteria and pitfalls. Am J Surg Pathol; 2005 Nov;29(11):1464-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Autoimmune pancreatitis (AIP) is a benign inflammatory disease of the pancreas that mimics pancreatic malignancy both clinically and radiologically.
  • There were three false-positive cytologic diagnoses, an adenocarcinoma, a solid-pseudopapillary tumor and a mucinous neoplasm.
  • Ductal epithelium was inconspicuous and was seen in 6 cases.
  • [MeSH-major] Adenocarcinoma / diagnosis. Autoimmune Diseases / diagnosis. Biopsy, Fine-Needle / methods. Endosonography. Pancreatic Neoplasms / diagnosis. Pancreatitis / diagnosis


56. Raemdonck TY, Van den Broecke CM, Claerhout I, Decock CE: Inverted papilloma arising primarily from the lacrimal sac. Orbit; 2009;28(2-3):181-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pathology following resection of the whole lacimal sac revealed the presence of an inverted papilloma (IP) with a sharp transition between the papilloma and the normal lacrimal duct epithelium.
  • An IP is a benign but infiltrative epithelial neoplasm with malignant potential characterised by a high recurrence rate.
  • [MeSH-minor] Contrast Media. Female. Follow-Up Studies. Humans. Immunohistochemistry. Neoplasm Invasiveness / pathology. Neoplasm Staging. Risk Assessment. Tomography, X-Ray Computed / methods. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19839908.001).
  • [ISSN] 1744-5108
  • [Journal-full-title] Orbit (Amsterdam, Netherlands)
  • [ISO-abbreviation] Orbit
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


57. Deng L, Broaddus RR, McCampbell A, Shipley GL, Loose DS, Stancel GM, Pickar JH, Davies PJ: Identification of a novel estrogen-regulated gene, EIG121, induced by hormone replacement therapy and differentially expressed in type I and type II endometrial cancer. Clin Cancer Res; 2005 Dec 1;11(23):8258-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The expression level of EIG121 was then measured by real-time quantitative reverse transcription-PCR in benign, hyperplastic, and malignant endometrial samples.
  • In endometrial complex, hyperplasia, and endometrioid adenocarcinoma, neoplastic proliferations associated with estrogen excess, the expression of EIG121 was significantly elevated (on average 3.8-fold in hyperplasias and 21-fold in grade 1 tumors).
  • Although the level of EIG121 mRNA in grade 3 endometrioid carcinoma was still 3.5-fold of that in benign endometrium, EIG121 expression tended to decline with increasing tumor grade and disease stage.
  • Immunohistochemistry showed faint staining of normal endometrial epithelium, but intense staining of endometrioid tumors.
  • In sharp contrast, EIG121 expression was significantly suppressed in both uterine papillary serous carcinoma and uterine malignant mixed mullerian tumor, two tumors not associated with estrogen exposure, to <5% of the level in benign endometrium.
  • [MeSH-major] Adenocarcinoma / genetics. Biomarkers, Tumor / genetics. Endometrial Neoplasms / genetics. Estrogen Replacement Therapy. Estrogens / therapeutic use. Gene Expression Regulation, Neoplastic / drug effects. Neoplasm Proteins / genetics

  • Genetic Alliance. consumer health - Endometrial cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ESTRONE .
  • SciCrunch. HGNC: Data: Gene Annotation .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16322283.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1P50CA098258-01; United States / NICHD NIH HHS / HD / 5T32 HD007324-18
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Estrogens; 0 / Estrogens, Conjugated (USP); 0 / KIAA1324 protein, human; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 2DI9HA706A / Estrone; QTL48N278K / estrone sulfate
  •  go-up   go-down


58. Kuijper A, de Vos RA, Lagendijk JH, van der Wall E, van Diest PJ: Progressive deregulation of the cell cycle with higher tumor grade in the stroma of breast phyllodes tumors. Am J Clin Pathol; 2005 May;123(5):690-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Progressive deregulation of the cell cycle with higher tumor grade in the stroma of breast phyllodes tumors.
  • We studied cell cycle-regulating proteins in phyllodes tumor pathogenesis by immunohistochemical analysis for Ki-67, cyclin A, cyclin D1, retinoblastoma protein (pRb), p53, p16INK4A, bcl-2, and p21waf1 in the epithelium and stroma of 40 primary (benign, 21; borderline, 8; malignant, 11) and 7 recurrent tumors of different grades.
  • In most cases, the epithelium showed no altered expression of cell cycle regulators.
  • Stromal overexpression of p16INK4A, p53, cyclin A, pRb, and p21waf1 correlated significantly with tumor grade.
  • Stromal cyclin A expression was the best separating marker between tumor grades.
  • No immunostaining differences were detected between primary tumors and recurrences.
  • The stromal component of mammary phyllodes tumors displays an increasing level of cell cycle deregulation with higher tumor grade; the epithelial compartment mostly remains inconspicuous.
  • Several combinations of aberrantly expressed cell cycle proteins seem important in the stromal progression of phyllodes tumors.
  • [MeSH-major] Breast Neoplasms / pathology. Cell Cycle. Cell Cycle Proteins / metabolism. Phyllodes Tumor / pathology. Stromal Cells / pathology
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Female. Humans. Immunoenzyme Techniques. Middle Aged. Neoplasm Proteins / metabolism. Neoplasm Recurrence, Local / metabolism. Neoplasm Recurrence, Local / pathology. Prognosis


59. Kalir T, Rahaman J, Hagopian G, Demopoulos R, Cohen C, Burstein DE: Immunohistochemical detection of glucose transporter GLUT1 in benign and malignant fallopian tube epithelia, with comparison to ovarian carcinomas. Arch Pathol Lab Med; 2005 May;129(5):651-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical detection of glucose transporter GLUT1 in benign and malignant fallopian tube epithelia, with comparison to ovarian carcinomas.
  • CONTEXT: Enhanced expression of GLUT1, a facilitative glucose transporter found on red blood cells, blood-brain barrier, and perineurium, has been described in a large spectrum of epithelial malignancies.
  • OBJECTIVE: We present an immunohistochemical survey of GLUT1 expression in benign and malignant fallopian tube epithelia, and compare serous carcinomas of the fallopian tube and ovary.
  • DESIGN: One hundred two routinely fixed and processed archival specimens (36 benign fallopian tubes, 29 primary tubal adenocarcinomas, and 37 primary ovarian adenocarcinomas) were immunostained with rabbit anti-GLUT1 and developed with streptavidin-biotin/diaminobenzidine.
  • RESULTS: Benign tubes (n = 36) were either negatively stained (58.3%) or displayed rare weak staining (0.5+ to 1+, rarely 2+; 41.7%); of the latter, 4 specimens showed chronic salpingitis, and 6 showed hyperplasia (epithelial tufting and stratification).
  • Nineteen tubal carcinoma sections showed residual benign epithelium, which was consistently nonstaining.
  • CONCLUSIONS: GLUT1 immunostaining of fallopian tube adenocarcinomas was substantially stronger and more extensive than staining of benign tubal epithelium, consistent with previously described findings in carcinomas versus benign tissues from many primary sites.
  • [MeSH-minor] Epithelial Cells / metabolism. Epithelial Cells / pathology. Female. Glucose Transporter Type 1. Humans. Hyperplasia / metabolism. Hyperplasia / pathology. Neoplasm Staging. Precancerous Conditions / metabolism. Precancerous Conditions / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15859637.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glucose Transporter Type 1; 0 / Monosaccharide Transport Proteins; 0 / SLC2A1 protein, human
  •  go-up   go-down


60. Guo J, Shou C, Meng L, Jiang B, Dong B, Yao L, Xie Y, Zhang J, Chen Y, Budman DR, Shi YE: Neuronal protein synuclein gamma predicts poor clinical outcome in breast cancer. Int J Cancer; 2007 Sep 15;121(6):1296-305
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Synuclein gamma (SNCG), previously identified as a breast cancer-specific gene (BCSG1), is highly expressed in breast carcinomas but not in normal epithelium.
  • Expression of SNCG was strongly correlated with the stage, lymph node involvement, metastasis, tumor size and Her-2 status, but its expression was not associated with ER and PR expression status.
  • While 71.4% of advanced breast cancers were positive for SNCG expression, only 26.8% of Stage I/II breast cancers were positive for SNCG expression and 5.2% of benign hyperplasia expressed SNCG.
  • After a median follow-up of 64 months, patients with an SNCG-positive tumor had a significantly shorter disease-free survival and overall survival and a high probability of death compared no expression of SNCG.
  • [MeSH-major] Biomarkers, Tumor / analysis. Breast Neoplasms / metabolism. Neoplasm Proteins / metabolism. gamma-Synuclein / metabolism
  • [MeSH-minor] Amino Acid Sequence. Animals. Antibodies, Monoclonal. Blotting, Western. Disease-Free Survival. Enzyme-Linked Immunosorbent Assay. Female. Gene Expression. Humans. Immunohistochemistry. Immunoprecipitation. Kaplan-Meier Estimate. Lymphatic Metastasis. Mice. Middle Aged. Molecular Sequence Data. Neoplasm Staging. Prognosis

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17534899.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / SNCG protein, human; 0 / gamma-Synuclein
  •  go-up   go-down


61. Tan TJ, Tan TY: CT features of parotid gland oncocytomas: a study of 10 cases and literature review. AJNR Am J Neuroradiol; 2010 Sep;31(8):1413-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Oncocytomas of the salivary glands are rare benign epithelial tumors which occur most commonly in the parotid gland.
  • The CT features of parotid oncocytomas in the largest imaging series of this rare but important benign lesion include a well-defined enhancing tumor with a "deformable" appearance when large, and a non-enhancing curvilinear cleft or cystic component.
  • These CT findings are potentially helpful in distinguishing these benign lesions from other parotid tumors in clinical scenarios that preclude surgical resection or when biopsy results are non-diagnostic.

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20395389.001).
  • [ISSN] 1936-959X
  • [Journal-full-title] AJNR. American journal of neuroradiology
  • [ISO-abbreviation] AJNR Am J Neuroradiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


62. Elayat G, Selim AG, Wells CA: Cell cycle alterations and their relationship to proliferation in apocrine adenosis of the breast. Histopathology; 2009 Feb;54(3):348-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIMS: Apocrine adenosis (AA) is generally considered a benign disease of the breast.
  • Furthermore, proliferation in AA (4.5%) was significantly higher than that of normal breast epithelium (1%).
  • [MeSH-minor] Adult. Aged. Breast Neoplasms / metabolism. Cell Cycle Proteins / metabolism. Female. Humans. Immunohistochemistry. Middle Aged. Neoplasm Invasiveness / pathology

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19236511.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cell Cycle Proteins
  •  go-up   go-down


63. Jeurnink SM, Vleggaar FP, Siersema PD: Overview of the clinical problem: facts and current issues of mucinous cystic neoplasms of the pancreas. Dig Liver Dis; 2008 Nov;40(11):837-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Intraductal papillary mucinous neoplasms are neoplasms with tall, columnar, mucin-containing epithelium involving the main pancreatic ducts or major side branches.
  • Serous cystic neoplasms appear as multiple cysts lined with cubic flat epithelium containing glycogen-rich cells with clear cytoplasm.
  • They mainly occur in women in their 50s and are generally benign.
  • As both mucinous cystic neoplasm and intraductal papillary mucinous neoplasms have a high malignant potential, it is important to differentiate between the various pancreatic cystic lesions.
  • Several imaging techniques and tumour markers have been evaluated.
  • A number of management issues regarding these neoplasms are still under debate, for example which imaging technique to use, differentiation between malignant or benign lesions and the preferred treatment modality for each pancreatic cystic neoplasm.
  • [MeSH-minor] Age Factors. Aged. Biomarkers, Tumor / analysis. Biopsy, Needle. Endosonography. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Staging. Pancreaticoduodenectomy / methods. Precancerous Conditions / pathology. Prognosis. Risk Assessment. Sex Factors. Survival Analysis. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18499541.001).
  • [ISSN] 1878-3562
  • [Journal-full-title] Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  • [ISO-abbreviation] Dig Liver Dis
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen
  • [Number-of-references] 46
  •  go-up   go-down


64. Scurry WC Jr, McGinn JD: Recurrent respiratory papillomatosis in pregnancy: a case of emergent airway management. Ear Nose Throat J; 2008 Jun;87(6):E8-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recurrent respiratory papillomatosis is a benign neoplastic process involving squamous epithelium of the respiratory tract, typically the vocal folds.
  • [MeSH-major] Laryngeal Neoplasms / surgery. Neoplasm Recurrence, Local / surgery. Papilloma / surgery. Pregnancy Complications, Neoplastic / surgery. Pregnancy Outcome


65. Sharma V, Koirala K: Lateral rhinotomy vs mid-facial degloving for T3 inverted papilloma of nose and paranasal sinus. Nepal Med Coll J; 2009 Jun;11(2):115-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Inverted papillomas are rare, benign epithelial tumours of the nasal cavity and paranasal sinuses.
  • All patients initially underwent nasal biopsy for confirmation of the diagnosis and pre-operative C.T. scan for tumour staging.
  • [MeSH-minor] Aged. Biopsy. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19968152.001).
  • [Journal-full-title] Nepal Medical College journal : NMCJ
  • [ISO-abbreviation] Nepal Med Coll J
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Nepal
  •  go-up   go-down


66. Burghaus S, Hölsken A, Buchfelder M, Fahlbusch R, Riederer BM, Hans V, Blümcke I, Buslei R: A tumor-specific cellular environment at the brain invasion border of adamantinomatous craniopharyngiomas. Virchows Arch; 2010 Mar;456(3):287-300
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A tumor-specific cellular environment at the brain invasion border of adamantinomatous craniopharyngiomas.
  • Craniopharyngiomas (CP) are benign epithelial tumors of the sellar region and can be clinicopathologically distinguished into adamantinomatous (adaCP) and papillary (papCP) variants.
  • Herein, we characterized the cellular interface between the tumor and the surrounding brain tissue in 48 CP (41 adaCP and seven papCP) compared to non-neuroepithelial tumors, i.e., 12 cavernous hemangiomas, 10 meningiomas, and 14 metastases using antibodies directed against glial fibrillary acid protein (GFAP), vimentin, nestin, microtubule-associated protein 2 (MAP2) splice variants, and tenascin-C.
  • We identified a specific cell population characterized by the coexpression of nestin, MAP2, and GFAP within the invasion niche of the adamantinomatous subtype.
  • Furthermore, the outer tumor cell layer of adaCP showed a distinct expression of MAP2, a novel finding helpful in the differential diagnosis of epithelial tumors in the sellar region.
  • Our data support the hypothesis that adaCP, unlike other non-neuroepithelial tumors of the central nervous system, create a tumor-specific cellular environment at the tumor-brain junction.
  • Whether this facilitates the characteristic infiltrative growth pattern or is the consequence of an activated Wnt signaling pathway, detectable in 90% of these tumors, will need further consideration.
  • [MeSH-minor] Adolescent. Adult. Aged. Biomarkers, Tumor / metabolism. Brain / metabolism. Child. Child, Preschool. Female. Gene Expression Regulation, Neoplastic. Glial Fibrillary Acidic Protein / metabolism. Humans. Intermediate Filament Proteins / metabolism. Male. Microtubule-Associated Proteins / metabolism. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasm Invasiveness / physiopathology. Neoplasm Metastasis / pathology. Neoplasm Metastasis / physiopathology. Nerve Tissue Proteins / metabolism. Nestin. Tenascin / metabolism. Vimentin / metabolism

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2006 Dec;30(12):1595-603 [17122517.001]
  • [Cites] Am J Pathol. 2002 Dec;161(6):1997-2001 [12466115.001]
  • [Cites] Neuropathol Appl Neurobiol. 2002 Dec;28(6):480-8 [12445164.001]
  • [Cites] Endocr Rev. 2006 Jun;27(4):371-97 [16543382.001]
  • [Cites] J Pathol. 2004 Jul;203(3):814-21 [15221941.001]
  • [Cites] Expert Rev Anticancer Ther. 2007 May;7(5):675-87 [17492931.001]
  • [Cites] Nat Cell Biol. 2001 Sep;3(9):778-84 [11533656.001]
  • [Cites] Brain Res. 2002 Jul 12;943(2):174-80 [12101039.001]
  • [Cites] Acta Neurochir (Wien). 2008 Dec;150(12):1213-26 [19002375.001]
  • [Cites] Oncogene. 2005 Dec 8;24(55):8200-4 [16091738.001]
  • [Cites] Glia. 2000 Feb 1;29(3):233-45 [10642750.001]
  • [Cites] Cancer Res. 1994 Jul 15;54(14):3897-904 [8033113.001]
  • [Cites] Acta Neuropathol. 2004 Aug;108(2):89-96 [15146346.001]
  • [Cites] Acta Neuropathol. 2005 Jun;109(6):589-97 [15891929.001]
  • [Cites] Brain Res Dev Brain Res. 2002 Nov 15;139(1):9-17 [12414089.001]
  • [Cites] J Neurochem. 1999 Dec;73(6):2531-7 [10582615.001]
  • [Cites] Glia. 1997 Jan;19(1):35-46 [8989566.001]
  • [Cites] J Biol Chem. 1990 Nov 15;265(32):19679-84 [2174050.001]
  • [Cites] Neurosurgery. 2005 Apr;56(4):763-76 [15792515.001]
  • [Cites] Brain Res Dev Brain Res. 1992 Feb 21;65(2):259-67 [1373996.001]
  • [Cites] Acta Neuropathol. 1978 Sep 15;43(3):191-203 [696237.001]
  • [Cites] Brain Pathol. 2009 Jul;19(3):357-64 [18540944.001]
  • [Cites] Pediatr Neurosurg. 1996 Nov;25(5):240-6; discussion 247 [9309787.001]
  • [Cites] Brain Res Dev Brain Res. 1992 Jul 24;68(1):111-23 [1521317.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Nov 21;92(24):10894-8 [7479905.001]
  • [Cites] J Cell Sci. 1994 Nov;107 ( Pt 11):3115-25 [7699010.001]
  • [Cites] Cell Tissue Res. 2003 Dec;314(3):315-24 [14523640.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] J Neurosurg. 2007 Jan;106(1 Suppl):3-12 [17233305.001]
  • [Cites] Matrix Biol. 2001 Feb;20(1):13-22 [11246000.001]
  • [Cites] J Neurosurg. 1999 Feb;90(2):237-50 [9950494.001]
  • [Cites] J Neurosurg. 1988 Aug;69(2):155-70 [3292716.001]
  • [Cites] Eur J Endocrinol. 2005 Apr;152(4):557-67 [15817911.001]
  • [Cites] J Neurosurg. 1990 Jul;73(1):12-7 [2352012.001]
  • [Cites] Horm Res. 2008;69(4):193-202 [18204266.001]
  • [Cites] Curr Drug Targets CNS Neurol Disord. 2005 Feb;4(1):85-92 [15723616.001]
  • [Cites] Lab Invest. 2002 Mar;82(3):345-51 [11896213.001]
  • [Cites] Clin Endocrinol (Oxf). 2005 Apr;62(4):397-409 [15807869.001]
  • [Cites] J Neuropathol Exp Neurol. 2001 Oct;60(10):984-93 [11589429.001]
  • [Cites] Annu Rev Cell Biol. 1989;5:71-92 [2480799.001]
  • [Cites] Curr Opin Pediatr. 2007 Aug;19(4):471-9 [17630614.001]
  • [Cites] Proc Natl Acad Sci U S A. 1985 Sep;82(17):6006-9 [3898077.001]
  • [Cites] Cancer Res. 2006 Dec 15;66(24):11771-80 [17178873.001]
  • [Cites] Glia. 1995 Apr;13(4):233-54 [7615335.001]
  • [Cites] Dev Dyn. 2004 May;230(1):1-11 [15108304.001]
  • [Cites] Brain Tumor Pathol. 2005;22(2):75-8 [18095108.001]
  • [Cites] J Neurosurg. 1998 Oct;89(4):547-51 [9761047.001]
  • [Cites] Eur J Neurosci. 2005 Oct;22(8):1863-72 [16262626.001]
  • [Cites] Pituitary. 2005;8(2):75-9 [16195780.001]
  • [Cites] Neurosurgery. 1994 Dec;35(6):1001-10; discussion 1010-1 [7885544.001]
  • [Cites] Acta Neuropathol. 2007 May;113(5):585-90 [17221204.001]
  • [Cites] Brain Res Dev Brain Res. 2002 Mar 31;134(1-2):87-92 [11947939.001]
  • [Cites] Cell. 1990 Feb 23;60(4):585-95 [1689217.001]
  • [Cites] Exp Neurol. 1999 Dec;160(2):348-60 [10619552.001]
  • [Cites] Eur J Endocrinol. 2008 Dec;159 Suppl 1:S95-9 [18775978.001]
  • [Cites] J Pediatr Endocrinol Metab. 2006 Apr;19 Suppl 1:453-4 [16700324.001]
  • [Cites] Cancer. 2003 Dec 1;98(11):2430-9 [14635078.001]
  • [Cites] J Neurosurg. 1995 Aug;83(2):206-14 [7616262.001]
  • [Cites] Neuropathology. 2007 Feb;27(1):1-9 [17319278.001]
  • (PMID = 20069432.001).
  • [ISSN] 1432-2307
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Glial Fibrillary Acidic Protein; 0 / Intermediate Filament Proteins; 0 / Microtubule-Associated Proteins; 0 / NES protein, human; 0 / Nerve Tissue Proteins; 0 / Nestin; 0 / Tenascin; 0 / Vimentin
  •  go-up   go-down


67. Burgos San Juan L: [Cholangiocarcinoma]. Rev Med Chil; 2008 Feb;136(2):240-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cholangiocarcinoma is a malignant lesion of the bile duct epithelium.
  • It is most frequently found in the confluence of the hepatic ducts, where it is called hilar cholangiocarcinoma or Klatskin tumor.
  • Hilar cholangiocarcinoma must be distinguished from other malignant or benign causes of biliary obstruction.
  • Cholangiocarcinoma of the distal common bile duct must be differentiated from other periampullary tumors and intrahepatic cholangiocarcinoma can be confused with a hepatocellular carcinoma.
  • The type and size of surgery depends on the location and extent of the tumor.
  • Patients with unresectable tumors can be subjected to palliative procedures such as biliary-enteric bypass, endoscopic or pecutaneous stent placement.
  • [MeSH-minor] Humans. Neoplasm Staging / methods

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18483680.001).
  • [ISSN] 0034-9887
  • [Journal-full-title] Revista médica de Chile
  • [ISO-abbreviation] Rev Med Chil
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Chile
  • [Number-of-references] 43
  •  go-up   go-down


68. Mirza S, Bradley PJ, Acharya A, Stacey M, Jones NS: Sinonasal inverted papillomas: recurrence, and synchronous and metachronous malignancy. J Laryngol Otol; 2007 Sep;121(9):857-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Inverted papillomas are relatively rare, benign epithelial tumours of the nasal cavity which generate considerable interest because they are locally aggressive, have a tendency to recur and are associated with malignancy.
  • [MeSH-major] Neoplasm Recurrence, Local / epidemiology. Papilloma, Inverted / epidemiology. Paranasal Sinus Neoplasms / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17319993.001).
  • [ISSN] 1748-5460
  • [Journal-full-title] The Journal of laryngology and otology
  • [ISO-abbreviation] J Laryngol Otol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 69
  •  go-up   go-down


69. Zhao XY, Schneider D, Biroc SL, Parry R, Alicke B, Toy P, Xuan JA, Sakamoto C, Wada K, Schulze M, Müller-Tiemann B, Parry G, Dinter H: Targeting tomoregulin for radioimmunotherapy of prostate cancer. Cancer Res; 2005 Apr 1;65(7):2846-53
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In contrast, radioimmunotherapy should still be efficacious in metastatic prostate cancer as radioisotopes are brought to tumor cells by targeting antibodies.
  • Immunohistochemical studies of tomoregulin protein in clinical samples show its location in the luminal epithelium of normal prostate, benign prostatic hyperplasia, and prostatic intraepithelial neoplasia.
  • More importantly, the tomoregulin protein is expressed in primary prostate tumors and in their lymph node and bone metastases.
  • The nature of tomoregulin as a transmembrane protein and its tissue-specific expression make tomoregulin an attractive target for radioimmunotherapy, in which tomoregulin-specific antibodies will deliver a radioisotope to prostate tumor cells and metastases.
  • Indeed, biodistribution studies using a prostate tumor xenograft model showed that the (111)In-labeled anti-tomoregulin antibody 2H8 specifically recognizes tomoregulin protein in vivo, leading to a strong tumor-specific accumulation of the antibody.
  • In efficacy studies, a single i.p. dose of 150 microCi (163 microg) (90)Y-labeled 2H8 substantially inhibits the growth rate of established LNCaP human prostate tumor xenograft in nude mice but produces no overt toxicity despite cross-reactivity of 2H8 with mouse tomoregulin.
  • [MeSH-major] Immunotoxins / therapeutic use. Indium Radioisotopes / therapeutic use. Membrane Proteins / biosynthesis. Neoplasm Proteins / biosynthesis. Prostatic Neoplasms / radiotherapy. Radioisotopes / therapeutic use. Ytterbium / therapeutic use
  • [MeSH-minor] Animals. Antibodies, Monoclonal / immunology. Antibodies, Monoclonal / pharmacokinetics. Antibodies, Monoclonal / therapeutic use. Brain / metabolism. Cell Line, Tumor. Humans. Immunoglobulin G / immunology. Immunoglobulin G / metabolism. Male. Mice. Mice, Nude. Neoplasm Metastasis. Prostate / metabolism. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. Radioimmunotherapy. Radiopharmaceuticals / immunology. Radiopharmaceuticals / pharmacokinetics. Radiopharmaceuticals / therapeutic use. Tissue Distribution. Xenograft Model Antitumor Assays

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15805286.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Immunoglobulin G; 0 / Immunotoxins; 0 / Indium Radioisotopes; 0 / Membrane Proteins; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / Radioisotopes; 0 / Radiopharmaceuticals; 0 / TMEFF2 protein, human; MNQ4O4WSI1 / Ytterbium
  •  go-up   go-down


70. Miura T, Igarashi Y, Okano N, Miki K, Okubo Y: Endoscopic diagnosis of intraductal papillary-mucinous neoplasm of the pancreas by means of peroral pancreatoscopy using a small-diameter videoscope and narrow-band imaging. Dig Endosc; 2010 Apr;22(2):119-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscopic diagnosis of intraductal papillary-mucinous neoplasm of the pancreas by means of peroral pancreatoscopy using a small-diameter videoscope and narrow-band imaging.
  • BACKGROUND: Intraductal papillary-mucinous neoplasm (IPMN) is an intraductal tumor in which the mucin-producing epithelium shows proliferated papillary and a wide variety of pathological changes ranging from hyperplasia to adenocarcinoma.
  • Therefore, it is important to determine whether an IPMN is benign or malignant.
  • We carried out the differential diagnosis of benign lesion to malignant lesion.
  • CONCLUSIONS: When combined with a videoscope and NBI, pancreatoscopy provided a clear image and was useful for evaluating whether the IPMN was benign or malignant.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20447205.001).
  • [ISSN] 1443-1661
  • [Journal-full-title] Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society
  • [ISO-abbreviation] Dig Endosc
  • [Language] eng
  • [Publication-type] Controlled Clinical Trial; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


71. Kovalenko S, Lukashenko P, Romanovskaya A, Soldatski IL, Bakanov SI, Pfister H, Gerein V: Distribution and density of CD1a+ and CD83+ dendritic cells in HPV-associated laryngeal papillomas. Int J Pediatr Otorhinolaryngol; 2009 Feb;73(2):249-56
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Respiratory papillomatosis associated with human papilloma virus (HPV) infection is the most common benign laryngeal neoplasm.
  • The correlation between dendritic cell (DC) density in tumor tissue and clinical prognosis was established.
  • The density of DC was analysed in epithelial layer and lamina propria.
  • RESULTS: In the epithelial layer of papillomas the number of CD1a+ and CD83+ DC was 86.2 (47.5-119.9) cells/mm(2) and 2.6 (0.6-7.9) cells/mm(2), respectively.
  • For subgroups of patients with high number of operations (more than 3), early disease onset (children under 3 years of age) and lingering duration of disease (more than 1 year) we detected an increase of CD83+ DC in the epithelial layer.
  • However, our data did not demonstrate a statistically significant difference in CD1a+ DC count neither in the epithelium nor in the lamina propria.
  • Probably, the increase of CD83+ DC density in epithelial layer of patients with severe course of disease can be an evidence of impaired migration of matured DC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19062106.001).
  • [ISSN] 0165-5876
  • [Journal-full-title] International journal of pediatric otorhinolaryngology
  • [ISO-abbreviation] Int. J. Pediatr. Otorhinolaryngol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD1; 0 / CD1a antigen; 0 / CD83 antigen; 0 / Immunoglobulins; 0 / Membrane Glycoproteins
  •  go-up   go-down


72. Schittenhelm J, Ebner FH, Harter P, Bornemann A: Symptomatic intraspinal oncocytic adrenocortical adenoma. Endocr Pathol; 2009;20(1):73-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Most intraspinal neoplasms of epithelial origin are metastases from primary carcinomas.
  • Benign epithelial tumors are rarely found at this site.
  • The excised tumor was composed of nests of large polygonal cells with eosinophilic partial granular cytoplasm.
  • The tumor showed diffuse positivity for melan-A, synaptophysin, and alpha-inhibin.
  • Ultrastructural examination showed abundant mitochondria, suggesting an oncocytic tumor.
  • These extraadrenal tumors are thought to arise from heterotopic adrenocortical tissue in the spinal cavity.
  • Oncocytic tumors are rare neoplasms and they comprise non-functioning variants of adrenal cortical adenomas.
  • To date, only five such intraspinal tumors have been observed.
  • Immunohistochemistry excluded oncocytic paraganglioma, oncocytic meningioma, renal cell carcinoma, alveolar soft part sarcoma, and granular cell tumor.
  • A view of the literature of these rare but probably underdiagnosed intraspinal tumors is given.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Radiol. 2005 Sep;60(9):953-9 [16124976.001]
  • [Cites] Pediatr Neurosurg. 2002 May;36(5):260-5 [12053045.001]
  • [Cites] Spinal Cord. 2007 Feb;45(2):183-6 [16505829.001]
  • [Cites] Am J Surg Pathol. 1998 Jan;22(1):57-63 [9422316.001]
  • [Cites] Int J Surg Pathol. 2004 Jul;12(3):259-64 [15306940.001]
  • [Cites] J Neurosurg. 2001 Apr;94(2 Suppl):310-2 [11302638.001]
  • [Cites] J Pediatr Surg. 1980 Jun;15(3):289-92 [6103925.001]
  • [Cites] Neurosurgery. 2006 Nov;59(5):E1144; discussion E1144 [17143207.001]
  • [Cites] Am J Surg Pathol. 1991 Oct;15(10 ):949-56 [1928551.001]
  • [Cites] Neurosurgery. 1993 Apr;32(4):658-61; discussion 661-2 [8474656.001]
  • [Cites] Histopathology. 1997 Aug;31(2):167-73 [9279569.001]
  • [Cites] Mol Cell Endocrinol. 2005 Apr 15;233(1-2):47-56 [15767045.001]
  • [Cites] Am J Surg Pathol. 1997 Apr;21(4):375-82 [9130983.001]
  • [Cites] J Med Case Rep. 2008 Jul 13;2:228 [18620603.001]
  • [Cites] Am J Surg Pathol. 1990 May;14(5):481-4 [2327553.001]
  • [Cites] Histopathology. 1986 Mar;10(3):311-9 [2422107.001]
  • [Cites] Fetal Pediatr Pathol. 2006 Jul-Aug;25(4):191-7 [17162526.001]
  • [Cites] J Clin Pathol. 1998 Feb;51(2):114-6 [9602683.001]
  • [Cites] AMA Arch Pathol. 1959 Feb;67(2):228-33 [13616833.001]
  • [Cites] Neurosurgery. 2000 Sep;47(3):756-9 [10981764.001]
  • [Cites] Int J Surg Pathol. 2004 Jul;12(3):231-43 [15306935.001]
  • (PMID = 19039533.001).
  • [ISSN] 1046-3976
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


73. Wang WB, Li YH, Liu B, Wang HS, Cui AR, Zhnag XH: [Correlation between PPARgamma and VEGF-C expression in extrahepatic cholangioadenocarcinoma (EHCAC) and their prognostic significance]. Zhonghua Zhong Liu Za Zhi; 2009 Oct;31(10):773-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: The expressions of PPARgamma and VEGF-C were detected by immunohistochemistry in 69 cases of EHCAC, 12 cases of non-tumor bile duct epithelium, and their relationship to clinicopathological parameters and follow-up were analyzed.
  • RESULTS: The positive rate of PPARgamma expression in 69 cases of EHCAC was 59.4%, significantly higher than that in 12 cases of non-tumor bile duct epithelium (0%), (P < 0.01).
  • The positive rate of VEGF-C in 69 cases of EHCAC was 84.1%, also significantly higher than 16.7% in 12 cases of benign bile duct epithelium (P < 0.05).
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Proportional Hazards Models. Survival Rate

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20021832.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / PPAR gamma; 0 / VEGFC protein, human; 0 / Vascular Endothelial Growth Factor C
  •  go-up   go-down


74. Mortuaire G, Pasquesoone X, Leroy X, Chevalier D: Respiratory epithelial adenomatoid hamartomas of the sinonasal tract. Eur Arch Otorhinolaryngol; 2007 Apr;264(4):451-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Respiratory epithelial adenomatoid hamartomas of the sinonasal tract.
  • We report the clinicopathologic features of two cases of respiratory epithelial adenomatoid harmartoma (REAH) of the sinonasal tract.
  • Histologically, these lesions were characterized by a glandular proliferation lined by ciliated respiratory epithelium originated from the surface epithelium.
  • Fine histopathological analysis is necessary to avoid aggressive surgery for this benign lesion.
  • [MeSH-major] Adenomatoid Tumor / pathology. Hamartoma / pathology. Paranasal Sinus Neoplasms / pathology. Respiratory Mucosa / pathology
  • [MeSH-minor] Adult. Endoscopy. Female. Humans. Middle Aged. Neoplasm Invasiveness

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2004 May;97(5):607-12 [15153874.001]
  • [Cites] Am J Otolaryngol. 2004 Jul-Aug;25(4):282-4 [15239039.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1995 Aug;104(8):639-45 [7639474.001]
  • [Cites] J Laryngol Otol. 2004 Jul;118(7):558-60 [15318966.001]
  • [Cites] Int J Pediatr Otorhinolaryngol. 2003 Jun;67(6):669-72 [12745162.001]
  • [Cites] Acta Otolaryngol. 2002 Jun;122(4):398-400 [12125996.001]
  • [Cites] Rev Laryngol Otol Rhinol (Bord). 2004;125(1):45-8 [15244029.001]
  • [Cites] Int J Pediatr Otorhinolaryngol. 2005 Jan;69(1):87-91 [15627453.001]
  • (PMID = 17089137.001).
  • [ISSN] 0937-4477
  • [Journal-full-title] European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  • [ISO-abbreviation] Eur Arch Otorhinolaryngol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


75. Ota T, Gilks CB, Longacre T, Leung PC, Auersperg N: HOXA7 in epithelial ovarian cancer: interrelationships between differentiation and clinical features. Reprod Sci; 2007 Sep;14(6):605-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HOXA7 in epithelial ovarian cancer: interrelationships between differentiation and clinical features.
  • Interrelationships between HOXA7 expression and ovarian cancer progression are investigated by cDNA array and by immunohistochemistry of normal ovaries and 538 epithelial ovarian tumor microarrays.
  • HOXA7 mRNA expression was higher in carcinomas than in benign tumors.
  • HOXA7 protein was absent in normal surface epithelium but appeared in metaplastic regions.
  • There were significant associations of strong HOXA7 staining of stroma and tumor nuclei with the clear cell histotype (stroma: P = .0022, nuclei: P = .0003) and of weak/absent staining with serous carcinomas.
  • Tumor E-cadherin expression correlated significantly with HOX7 staining in stroma (P = .0002) but not within tumors.
  • HOXA7 staining of tumor cell nuclei is correlated significantly with improved disease-specific survival (P = .0104), which is suggestive of the biological and potentially clinical importance of subcellular HOXA7 localization.
  • [MeSH-major] Adenocarcinoma, Clear Cell / chemistry. Adenocarcinoma, Mucinous / chemistry. Biomarkers, Tumor / analysis. Carcinoma, Endometrioid / chemistry. Cell Differentiation. Cystadenocarcinoma, Serous / chemistry. Homeodomain Proteins / analysis. Ovarian Neoplasms / chemistry
  • [MeSH-minor] Cadherins / analysis. Cell Nucleus / chemistry. Cluster Analysis. Female. Gene Expression Profiling / methods. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Metaplasia. Neoplasm Staging. Oligonucleotide Array Sequence Analysis. Prognosis. Stromal Cells / chemistry. Stromal Cells / pathology. Tissue Array Analysis


76. Huang P, Staerkel G, Sneige N, Gong Y: Fine-needle aspiration of pancreatic serous cystadenoma: cytologic features and diagnostic pitfalls. Cancer; 2006 Aug 25;108(4):239-49
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The preoperative diagnosis of pancreatic serous cystadenoma (SCA) is important because as a typically benign tumor it can be treated expectantly, whereas many other cystic tumors require excision.
  • This study examines the cytology, clinical and radiologic features, diagnostic accuracy of fine-needle aspiration (FNA), and potential pitfalls associated with this rare tumor.
  • Corresponding histology (14 tumors) and clinical/imaging findings were also evaluated.
  • Tumor cells formed loose clusters or monolayered sheets composed of cuboidal cells with indistinct cell borders and granular or clear cytoplasm that was often stripped from the nucleus.
  • Seven (25%) of the aspirates were initially classified as "consistent with SCA," 6 (21%) as "no malignant cells," 3 (11%) as "nondiagnostic specimen," 3 (11%) as "suspicious for malignancy," 3 (11%) as "rare atypical cells," and 6 (21%) as "probably or consistent with mucinous cystic neoplasm."
  • Gastrointestinal (GI) epithelium and mucin also caused confusion.
  • Familiarity with its morphologic spectrum, use of ancillary studies, and correlation with clinical/radiologic findings greatly improves diagnostic accuracy.
  • Contaminating GI epithelium and mucin should be distinguished from components of a mucinous neoplasm.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 American Cancer Society.
  • (PMID = 16691573.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


77. Higgins JP, Kaygusuz G, Wang L, Montgomery K, Mason V, Zhu SX, Marinelli RJ, Presti JC Jr, van de Rijn M, Brooks JD: Placental S100 (S100P) and GATA3: markers for transitional epithelium and urothelial carcinoma discovered by complementary DNA microarray. Am J Surg Pathol; 2007 May;31(5):673-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Placental S100 (S100P) and GATA3: markers for transitional epithelium and urothelial carcinoma discovered by complementary DNA microarray.
  • The morphologic distinction between prostate and urothelial carcinoma can be difficult.
  • Together with our prior studies on renal neoplasms and normal kidney, these studies suggested that the gene for placental S100 (S100P) is specifically expressed in benign and malignant urothelial cells.
  • A second gene, GATA3, also showed high level expression in urothelial tumors by cDNA array.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / metabolism. Calcium-Binding Proteins / metabolism. Carcinoma, Transitional Cell / metabolism. GATA3 Transcription Factor / metabolism. Neoplasm Proteins / metabolism. Urologic Neoplasms / metabolism
  • [MeSH-minor] Carcinoma, Renal Cell / genetics. Carcinoma, Renal Cell / metabolism. Carcinoma, Renal Cell / pathology. DNA, Neoplasm / analysis. Diagnosis, Differential. Female. Gene Expression Profiling. Humans. Immunohistochemistry. Kidney Neoplasms / genetics. Kidney Neoplasms / metabolism. Kidney Neoplasms / pathology. Male. Nephrectomy. Oligonucleotide Array Sequence Analysis. Prostatic Neoplasms / genetics. Prostatic Neoplasms / metabolism. Prostatic Neoplasms / pathology. Tissue Array Analysis. Urinary Bladder Neoplasms / genetics. Urinary Bladder Neoplasms / metabolism. Urinary Bladder Neoplasms / pathology. Urothelium / metabolism. Urothelium / pathology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17460449.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Calcium-Binding Proteins; 0 / DNA, Neoplasm; 0 / GATA3 Transcription Factor; 0 / GATA3 protein, human; 0 / Neoplasm Proteins; 0 / S100P protein, human
  •  go-up   go-down


78. Halbritter SA, Altermatt HJ, Caversaccio M, Bornstein MM: Apocrine papillary cystadenoma of a minor salivary gland on the lower lip: case presentation. Quintessence Int; 2009 Feb;40(2):167-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cystadenomas are a rare, painless, and slow-growing benign epithelial tumor of the salivary gland.

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19169449.001).
  • [ISSN] 1936-7163
  • [Journal-full-title] Quintessence international (Berlin, Germany : 1985)
  • [ISO-abbreviation] Quintessence Int
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


79. Xiang H, Ding W, Liu F, Ren GP, Wang ZM, Zhu XZ: [Clinicopathologic analysis of mixed epithelial and stromal tumor of kidney and adult cystic nephroma]. Zhonghua Bing Li Xue Za Zhi; 2009 Jul;38(7):436-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinicopathologic analysis of mixed epithelial and stromal tumor of kidney and adult cystic nephroma].
  • OBJECTIVE: To study the clinicopathologic features, immunophenotype and differential diagnosis of mixed epithelial and stromal tumor of kidney (MEST) and adult cystic nephroma (CN).
  • The glandular structures in 2 of the cases were partially lined by endometrial or tubal epithelium.
  • In contrast, the thin-walled cystic spaces in CN were lined by a single layer of epithelium.Immunohistochemical study showed that the epithelial cells were positive for pan-cytokeratin and epithelial membrane antigen.
  • CONCLUSIONS: Both MEST and CN are uncommon renal neoplasm.
  • Most of them run a benign clinical course.
  • [MeSH-major] Epithelial Cells / pathology. Kidney Neoplasms / pathology. Neoplasms, Complex and Mixed / pathology. Neoplasms, Cystic, Mucinous, and Serous / pathology. Stromal Cells / pathology

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19781188.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / ACTA2 protein, human; 0 / Actins; 0 / Desmin; 0 / Receptors, Estrogen; 0 / Vimentin
  •  go-up   go-down


80. Kekeeva TV, Popova OP, Shegaĭ PV, Alekseev BIa, Adnreeva IuIu, Zaletaev DV, Nemtsova MV: [Abberant methylation of p16, HIC1, N33 and GSTP1 genes in tumor epitelium and tumor-associated stromal cells of prostate cancer]. Mol Biol (Mosk); 2007 Jan-Feb;41(1):79-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Abberant methylation of p16, HIC1, N33 and GSTP1 genes in tumor epitelium and tumor-associated stromal cells of prostate cancer].
  • Tumor epithelia, tumor-associated stroma, normal epithelia, foci of PIN and benign prostate hyperplasia, and stroma adjacent to tumor tissues were isolated from whole-mount prostatectomy specimens of patients with localized prostate cancer by using laser capture microdissection.
  • We found high levels of gene methylation in the tumor epithelium and tumor-associated stromal cells and some methylation in both hyperplastic epithelium and stromal cells in normal-appearing tissues located adjacent to tumors.
  • Promoter methylation in the non-neoplastic cells of the prostate tumor microenvironment may play an important role in cancer development and progression.
  • Methylation frequencies of all genes in tumor samples were considerably lower than frequencies in microdissected tumour samples (HIC1, 71 versus 89%; p16, 22 versus 78%; GSTP1, 32 versus 100%; N33, 20 versus 33%).
  • [MeSH-major] DNA Methylation. Genes, p16. Glutathione S-Transferase pi / genetics. Kruppel-Like Transcription Factors / genetics. Neoplasm Proteins / genetics. Prostatic Neoplasms / genetics
  • [MeSH-minor] Epithelial Cells / pathology. Humans. Male. Microdissection. Middle Aged. Stromal Cells / pathology

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17380894.001).
  • [ISSN] 0026-8984
  • [Journal-full-title] Molekuliarnaia biologiia
  • [ISO-abbreviation] Mol. Biol. (Mosk.)
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / HIC1 protein, human; 0 / Kruppel-Like Transcription Factors; 0 / Neoplasm Proteins; EC 2.5.1.18 / Glutathione S-Transferase pi
  •  go-up   go-down


81. Chung EM, Cube R, Lewis RB, Conran RM: From the archives of the AFIP: Pediatric liver masses: radiologic-pathologic correlation part 1. Benign tumors. Radiographics; 2010 May;30(3):801-26
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] From the archives of the AFIP: Pediatric liver masses: radiologic-pathologic correlation part 1. Benign tumors.
  • Benign hepatic tumors in children include lesions that are unique to the pediatric age group and others that are more common in adults.
  • Infantile hemangioendothelioma, or infantile hepatic hemangioma, is a benign vascular tumor that may cause serious clinical complications.
  • The mesenchymal component or cystic component may predominate; this predominance determines the imaging appearance of the tumor.
  • Benign epithelial tumors that are common in adults may infrequently occur in childhood.
  • Knowledge of how the pathologic features of these tumors affect their imaging appearances helps radiologists offer an appropriate differential diagnosis and management plan.

  • MedlinePlus Health Information. consumer health - Diagnostic Imaging.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20462995.001).
  • [ISSN] 1527-1323
  • [Journal-full-title] Radiographics : a review publication of the Radiological Society of North America, Inc
  • [ISO-abbreviation] Radiographics
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


82. Tomlins SA, Mehra R, Rhodes DR, Cao X, Wang L, Dhanasekaran SM, Kalyana-Sundaram S, Wei JT, Rubin MA, Pienta KJ, Shah RB, Chinnaiyan AM: Integrative molecular concept modeling of prostate cancer progression. Nat Genet; 2007 Jan;39(1):41-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Using laser-capture microdissection to isolate 101 cell populations, we have profiled prostate cancer progression from benign epithelium to metastatic disease.
  • [MeSH-minor] Androgens / metabolism. Disease Progression. Humans. Male. Neoplasm Metastasis. Prostatic Hyperplasia / genetics. Prostatic Hyperplasia / pathology. Prostatic Intraepithelial Neoplasia / genetics. Prostatic Intraepithelial Neoplasia / pathology. Signal Transduction. Systems Integration

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17173048.001).
  • [ISSN] 1061-4036
  • [Journal-full-title] Nature genetics
  • [ISO-abbreviation] Nat. Genet.
  • [Language] eng
  • [Databank-accession-numbers] GEO/ GSE6099
  • [Grant] United States / NCI NIH HHS / CA / 5P30 CA46592; United States / NCI NIH HHS / CA / P50CA69568; United States / NCI NIH HHS / CA / R01 CA102872; United States / NIDA NIH HHS / DA / U54 DA021519-01A1; United States / NCI NIH HHS / CA / UO1 CA111275-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Androgens
  •  go-up   go-down


83. Bhalla RK, Wright ED: Predicting the site of attachment of sinonasal inverted papilloma. Rhinology; 2009 Dec;47(4):345-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • STATEMENT OF PROBLEM: Sinonasal inverted papilloma is a benign, epithelial neoplasm, which has a propensity for malignant transformation and recurrence.
  • The evolution of endoscopic trans-nasal surgery has facilitated less destructive and, more functionally and cosmetically acceptable approaches to this tumour.
  • Precise surgery is enhanced by pre-operative localisation of the site of tumour attachment.
  • Intra-operatively, the actual site of tumour attachment was established.
  • A correlation between the predicted and actual site of tumour attachment was calculated.

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19936356.001).
  • [ISSN] 0300-0729
  • [Journal-full-title] Rhinology
  • [ISO-abbreviation] Rhinology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


84. Calcaterra R, Franco G, Valenzano M, Fazio R, Morrone A: Clinical features and treatment of dermatosis papulosa nigra in migrants to Italy. Skinmed; 2010 Jul-Aug;8(4):207-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Dermatosis papulosa nigra (DPN) is a benign epithelial tumor that is common in dark-skinned people.
  • Therefore, even if DPN is a benign disease, the lesions are unaesthetic and the therapeutic options are quite inefficient.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21137605.001).
  • [ISSN] 1540-9740
  • [Journal-full-title] Skinmed
  • [ISO-abbreviation] Skinmed
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


85. Miot HA, Miot LD, da Costa AL, Matsuo CY, Stolf HO, Marques ME: Association between solitary keratoacanthoma and cigarette smoking: a case-control study. Dermatol Online J; 2006;12(2):2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Solitary keratoacanthoma (KA) is a common benign epithelial tumor of the skin characterized by rapid growth and a tendency toward spontaneous regression.
  • The exact etiology and classification of KA are a matter of debate.

  • Genetic Alliance. consumer health - Keratoacanthoma.
  • MedlinePlus Health Information. consumer health - Smoking.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16638395.001).
  • [ISSN] 1087-2108
  • [Journal-full-title] Dermatology online journal
  • [ISO-abbreviation] Dermatol. Online J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


86. Lin TY, Zhang AY, Bayer-Garner IB, Krell JM, Acker SM: Epithelial sheath neuroma: a case report and discussion of the literature. Am J Dermatopathol; 2006 Jun;28(3):216-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epithelial sheath neuroma: a case report and discussion of the literature.
  • Here, a case of a rare epithelial sheath neuroma (ESN) is reported.
  • ESN is characterized by enlarged nerve fibers ensheathed by a sometimes keratinized squamous epithelium located in the superficial dermis where large nerves are not normally found.
  • It is believed to be a benign neoplasm and simple excision is curative.
  • [MeSH-minor] Dermis / pathology. Epithelium / pathology. Female. Humans. Middle Aged

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16778489.001).
  • [ISSN] 0193-1091
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 16
  •  go-up   go-down


87. Zhao H, Mandich D, Cartun RW, Ligato S: Expression of K homology domain containing protein overexpressed in cancer in pancreatic FNA for diagnosing adenocarcinoma of pancreas. Diagn Cytopathol; 2007 Nov;35(11):700-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We evaluated the immunocytochemical (ICC) expression of K homology domain containing protein overexpressed in cancer (KOC) in pancreatic endoscopic ultrasound-guided fine needle aspirates (EUS-FNAs) to assess its potential use as an adjunct in differentiating nonneoplastic (GI epithelium) and benign neoplastic epithelia (benign epithelial pancreatic neoplasms) from pancreatic adenocarcinoma cells.
  • KOC expression was present in 35/40 (88%) of adenocarcinomas (Ac) and was negative in all eight benign cases.
  • We conclude that KOC ICC expression on alcohol-fixed smears along with cytology improves the sensitivity of EUS-FNAs in the diagnosis of pancreatic Ac, and KOC reactivity is especially useful in differentiating Ac from nonneoplastic gastrointestinal epithelium and benign neoplastic epithelia.
  • [MeSH-major] Adenocarcinoma / diagnosis. Biopsy, Fine-Needle. Neoplasm Proteins / analysis. Pancreatic Neoplasms / diagnosis. RNA-Binding Proteins / analysis

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17924416.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / IMP3 protein, human; 0 / Neoplasm Proteins; 0 / RNA-Binding Proteins
  •  go-up   go-down


88. Poli Neto OB, Candido Dos Reis FJ, Zambelli Ramalho LN, Nogueira AA, de Andrade JM: p63 expression in epithelial ovarian tumors. Int J Gynecol Cancer; 2006 Jan-Feb;16(1):152-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p63 expression in epithelial ovarian tumors.
  • The p63 is a homologue gene of the tumor suppressor p53. p63 appears to be important for the development and differentiation of reproductive epithelium and interacts with p53 in human tumorigenesis.
  • This study presents the immunoexpression of the p63 in benign and malignant epithelial ovarian tumors.
  • We evaluated the p63 immunoexpression in 91 ovarian benign cystadenomas (29 mucinous and 62 serous) and in 29 ovarian malignant tumors (3 mucinous borderline, 3 serous borderline, 17 serous carcinomas, 2 endometrioid, 2 undifferentiated, 1 mucinous, and 1 clear-cell carcinoma) using a monoclonal antibody clone 4A4 (1:200), which recognizes all p63 variants.
  • The tumors were considered p63 positive if 5% or more cells presented nuclear immunostaining.
  • We observed 85.7% of positivity in benign tumors, 50% in borderline tumors, and 8.7% in invasive ovarian cancer (P < .0001).
  • The benign serous cystadenomas were positive in 91.9% of cases and benign mucinous cystadenomas in 72.4% (P= .02).
  • These data suggests an important role of p63 in the control of ovarian epithelium behavior.
  • The p63 may be involved in the development of benign and malignant epithelial ovarian tumors.
  • [MeSH-minor] Adult. Age Factors. Biomarkers, Tumor / analysis. Biopsy, Needle. Cohort Studies. DNA-Binding Proteins. Female. Gene Expression Regulation, Neoplastic. Genes, Tumor Suppressor. Humans. Immunohistochemistry. Middle Aged. Neoplasm Staging. Probability. Prognosis. Risk Assessment. Sensitivity and Specificity. Tissue Culture Techniques. Transcription Factors. Tumor Suppressor Proteins

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16445626.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Phosphoproteins; 0 / TP63 protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


89. Drieschner N, Kerschling S, Soller JT, Rippe V, Belge G, Bullerdiek J, Nimzyk R: A domain of the thyroid adenoma associated gene (THADA) conserved in vertebrates becomes destroyed by chromosomal rearrangements observed in thyroid adenomas. Gene; 2007 Nov 15;403(1-2):110-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • THADA, mapping to chromosomal band 2p21 is target gene of specific chromosomal rearrangements observed in thyroid benign tumors.
  • Thus, it is one of the most common gene targets in chromosomal rearrangements in benign epithelial tumors.
  • [MeSH-major] Adenoma / genetics. Chromosome Aberrations. Gene Rearrangement. Neoplasm Proteins / genetics. Thyroid Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17889454.001).
  • [ISSN] 0378-1119
  • [Journal-full-title] Gene
  • [ISO-abbreviation] Gene
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / DNA, Complementary; 0 / Neoplasm Proteins; 0 / RNA, Messenger
  •  go-up   go-down


90. Furusato B, Shaheduzzaman S, Petrovics G, Dobi A, Seifert M, Ravindranath L, Nau ME, Werner T, Vahey M, McLeod DG, Srivastava S, Sesterhenn IA: Transcriptome analyses of benign and malignant prostate epithelial cells in formalin-fixed paraffin-embedded whole-mounted radical prostatectomy specimens. Prostate Cancer Prostatic Dis; 2008;11(2):194-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transcriptome analyses of benign and malignant prostate epithelial cells in formalin-fixed paraffin-embedded whole-mounted radical prostatectomy specimens.
  • Furthermore, to increase the sample quality, we utilized laser capture microdissection of prostate tumor and benign epithelial cells.
  • [MeSH-major] Adenocarcinoma / genetics. Epithelial Cells / metabolism. Gene Expression Profiling. Neoplasm Proteins / genetics. Prostate / metabolism. Prostatic Neoplasms / genetics. RNA, Messenger / genetics. RNA, Neoplasm / genetics. Tissue Preservation / methods

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. FORMALDEHYDE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17768422.001).
  • [ISSN] 1476-5608
  • [Journal-full-title] Prostate cancer and prostatic diseases
  • [ISO-abbreviation] Prostate Cancer Prostatic Dis.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 1HG84L3525 / Formaldehyde
  •  go-up   go-down


91. Virk R, Lu D: Mucinous adenocarcinoma as heterologous element in intermediately differentiated Sertoli-Leydig cell tumor of the ovary. Pathol Res Pract; 2010 Jul 15;206(7):489-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucinous adenocarcinoma as heterologous element in intermediately differentiated Sertoli-Leydig cell tumor of the ovary.
  • Sertoli-Leydig cell tumor (SLCT) is a rare tumor involving the ovary.
  • The gastrointestinal-type epithelium is the most commonly described endodermal heterologous element.
  • SLCT with benign and borderline mucinous neoplasm has been reported in the literature.
  • Herein, we describe a rare case of intermediately differentiated Sertoli-Leydig cell tumor with mucinous adenocarcinoma as the heterologous element in a 21-year-old woman.
  • Microscopically, the tumor was composed of intermediately differentiated Sertoli-Leydig cell tumor and well-differentiated mucinous adenocarcinoma.
  • Interestingly, the bulk of the tumor (more than 90%) was composed of mucinous adenocarcinoma, whereas the SLCT component comprised less than 10% of the total tumor.
  • This case was a diagnostic challenge as more than 90% of the tumor was composed of mucinous adenocarcinoma and SLCT constituted only the minor part of the tumor.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Ovarian Neoplasms / pathology. Sertoli-Leydig Cell Tumor / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009. Published by Elsevier GmbH.
  • (PMID = 19674851.001).
  • [ISSN] 1618-0631
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


92. Donoiu I, Radu RI, Giucă A, Popescu M, Ionescu DD: Invasive thymoma. Rom J Morphol Embryol; 2010;51(3):573-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Thymomas are rare tumors of the thymic epithelium with a broad spectrum of morphological and clinical features.
  • Despite a benign histological appearance, it can invade nearby structures or metastasize.
  • According to the WHO Classification, there are six histologic types of thymic epithelial tumors.
  • [MeSH-minor] Humans. Lung / pathology. Lung / radiography. Middle Aged. Neoplasm Invasiveness. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20809041.001).
  • [ISSN] 1220-0522
  • [Journal-full-title] Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie
  • [ISO-abbreviation] Rom J Morphol Embryol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


93. Kaur J, Dey P: Micronucleus to distinguish adenocarcinoma from reactive mesothelial cell in effusion fluid. Diagn Cytopathol; 2010 Mar;38(3):177-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The scoring of MNC can be used as an additional biomarker and to discriminate between benign reactive mesothelial cells versus metastatic adenocarcinoma in effusion fluids in difficult situation.
  • [MeSH-minor] Adult. Aged. Cell Proliferation. Diagnosis, Differential. Epithelium / pathology. Female. Humans. Male. Middle Aged. Neoplasm Metastasis / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19693939.001).
  • [ISSN] 1097-0339
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


94. Iezzi G, Piattelli A, Rubini C, Artese L, Fioroni M, Carinci F: MIB-1, Bcl-2 and p53 in odontogenic myxomas of the jaws. Acta Otorhinolaryngol Ital; 2007 Oct;27(5):237-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Odontogenic myxoma is a rare benign neoplasm occurring in the jaws.
  • In some cases (20%), odontogenic epithelial islands may be found.
  • The Authors evaluated p53, MIB-1, and Bcl-2 expressed by the epithelial and stromal elements in 12 cases of odontogenic myxoma of the jaws.
  • The cells of the odontogenic epithelium were positive for Bcl-2, p53 and MIB-1.
  • Proliferation of both the epithelial and stromal components could be related to the growth of this odontogenic tumour.
  • [MeSH-major] Genes, bcl-2 / genetics. Genes, p53 / genetics. Mandibular Neoplasms / genetics. Mandibular Neoplasms / pathology. Myxoma / genetics. Myxoma / pathology. Odontogenic Tumors / genetics. Odontogenic Tumors / pathology. Ubiquitin-Protein Ligases / genetics
  • [MeSH-minor] Adolescent. Adult. Humans. Middle Aged. Neoplasm Staging

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Oral Pathol Med. 2002 Aug;31(7):415-20 [12165060.001]
  • [Cites] Life Sci. 2003 Oct 17;73(22):2865-72 [14511771.001]
  • [Cites] J Oral Maxillofac Surg. 2003 Dec;61(12):1463-6 [14663812.001]
  • [Cites] Oncol Res. 2005;15(5):249-55 [16261844.001]
  • [Cites] Int J Exp Pathol. 2005 Dec;86(6):375-81 [16309543.001]
  • [Cites] Anticancer Res. 2005 Nov-Dec;25(6C):4699-706 [16334163.001]
  • [Cites] J Clin Periodontol. 2006 Jan;33(1):76-8 [16367860.001]
  • [Cites] J Oral Pathol Med. 2006 Jul;35(6):369-75 [16762018.001]
  • [Cites] Int J Oral Maxillofac Surg. 2006 Aug;35(8):750-5 [16690252.001]
  • [Cites] J Oral Maxillofac Surg. 2006 Sep;64(9):1343-52 [16916667.001]
  • [Cites] J Craniomaxillofac Surg. 2004 Jun;32(3):161-5 [15113574.001]
  • [Cites] Int J Oral Maxillofac Surg. 2004 Jun;33(4):333-7 [15145033.001]
  • [Cites] Oral Oncol. 2004 Oct;40(9):954-9 [15380175.001]
  • [Cites] J Clin Pathol. 1973 Aug;26(8):570-82 [4354841.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1975 Jun;39(6):901-17 [1055976.001]
  • [Cites] J Oral Pathol. 1977 Nov;6(6):343-58 [412928.001]
  • [Cites] J Oral Pathol. 1985 Apr;14(4):299-306 [3923172.001]
  • [Cites] J Maxillofac Surg. 1986 Feb;14(1):46-52 [3456413.001]
  • [Cites] J Oral Pathol Med. 1991 Mar;20(3):114-9 [2037972.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1992;420(5):377-83 [1375793.001]
  • [Cites] Eur J Cancer B Oral Oncol. 1994;30B(2):126-31 [7913362.001]
  • [Cites] Eur J Cancer B Oral Oncol. 1994;30B(2):138-41 [8032302.001]
  • [Cites] Eur J Cancer B Oral Oncol. 1994 Nov;30B(6):377-80 [7536506.001]
  • [Cites] Eur J Cancer B Oral Oncol. 1994 Nov;30B(6):419-23 [7719225.001]
  • [Cites] J Oral Maxillofac Surg. 1995 May;53(5):518-21 [7722719.001]
  • [Cites] Mod Pathol. 1995 Feb;8(2):150-4 [7777475.001]
  • [Cites] Histopathology. 1995 Mar;26(3):219-28 [7797199.001]
  • [Cites] J Oral Pathol Med. 1995 May;24(5):221-6 [7542341.001]
  • [Cites] J Clin Pathol. 1995 Aug;48(8):759-62 [7560205.001]
  • [Cites] J Oral Pathol Med. 1995 Aug;24(7):313-5 [7473268.001]
  • [Cites] Int J Oral Maxillofac Surg. 1995 Jun;24(3):221-5 [7594756.001]
  • [Cites] Hum Pathol. 1996 Feb;27(2):102-10 [8617450.001]
  • [Cites] J Pathol. 1996 Apr;178(4):393-7 [8691316.001]
  • [Cites] Eur J Cancer B Oral Oncol. 1996 May;32B(3):143-9 [8762869.001]
  • [Cites] Cancer Lett. 1996 Aug 2;105(2):139-46 [8697436.001]
  • [Cites] Eur J Cancer B Oral Oncol. 1995 Nov;31B(6):380-3 [8746268.001]
  • [Cites] Eur J Cancer B Oral Oncol. 1995 Nov;31B(6):392-5 [8746270.001]
  • [Cites] Eur J Cancer B Oral Oncol. 1995 Nov;31B(6):403-4 [8746274.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1996 Oct;82(4):426-33 [8899782.001]
  • [Cites] Eur J Cancer B Oral Oncol. 1996 Sep;32B(5):328-32 [8944836.001]
  • [Cites] Eur J Cancer B Oral Oncol. 1996 Nov;32B(6):394-400 [9039223.001]
  • [Cites] J Clin Pathol. 1997 Jan;50(1):33-6 [9059353.001]
  • [Cites] Pathol Res Pract. 1997;193(1):1-7 [9112268.001]
  • [Cites] J Pathol. 1997 Aug;182(4):392-7 [9306959.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1997 Dec;84(6):672-5 [9431538.001]
  • [Cites] Oral Oncol. 1997 Nov;33(6):419-25 [9509126.001]
  • [Cites] Pathol Res Pract. 1998;194(5):309-17 [9651943.001]
  • [Cites] J Pathol. 1998 Apr;184(4):360-8 [9664901.001]
  • [Cites] J Oral Pathol Med. 1998 May;27(5):191-6 [9682980.001]
  • [Cites] Anticancer Res. 1998 Nov-Dec;18(6A):4415-7 [9891502.001]
  • [Cites] J Clin Pathol. 1998 Oct;51(10):716-24 [10023332.001]
  • [Cites] Mol Pathol. 1998 Oct;51(5):254-61 [10193519.001]
  • [Cites] J Oral Pathol Med. 2005 Jan;34(1):46-52 [15610406.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005 Feb;99(2):191-5 [15660091.001]
  • [Cites] J Oral Pathol Med. 2005 May;34(5):257-62 [15817067.001]
  • [Cites] J Oral Maxillofac Surg. 2005 Jun;63(6):811-9 [15944979.001]
  • [Cites] Int Endod J. 2005 Jul;38(7):465-9 [15946267.001]
  • [Cites] Int J Oral Maxillofac Surg. 2005 Jun;34(4):432-5 [16053855.001]
  • [Cites] Anticancer Res. 2005 May-Jun;25(3c):2589-92 [16080498.001]
  • [Cites] Genes Chromosomes Cancer. 2005 Oct;44(2):204-11 [16001434.001]
  • [Cites] J Oral Pathol Med. 2005 Nov;34(10):602-7 [16202080.001]
  • [Cites] Head Neck. 2005 Nov;27(11):982-9 [16136583.001]
  • [Cites] J Clin Pathol. 2005 Nov;58(11):1157-62 [16254104.001]
  • [Cites] Semin Diagn Pathol. 1999 Nov;16(4):297-301 [10587272.001]
  • [Cites] J Oral Pathol Med. 2000 Mar;29(3):129-38 [10738940.001]
  • [Cites] J Oral Pathol Med. 2000 Mar;29(3):139-44 [10738941.001]
  • [Cites] J Laryngol Otol. 2000 Jul;114(7):533-5 [10992937.001]
  • (PMID = 18198753.001).
  • [ISSN] 0392-100X
  • [Journal-full-title] Acta otorhinolaryngologica Italica : organo ufficiale della Società italiana di otorinolaringologia e chirurgia cervico-facciale
  • [ISO-abbreviation] Acta Otorhinolaryngol Ital
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] EC 6.3.2.19 / MIB1 ligase, human; EC 6.3.2.19 / Ubiquitin-Protein Ligases
  • [Other-IDs] NLM/ PMC2640038
  •  go-up   go-down


95. Thomas S, Chigurupati S, Anbalagan M, Shah G: Calcitonin increases tumorigenicity of prostate cancer cells: evidence for the role of protein kinase A and urokinase-type plasminogen receptor. Mol Endocrinol; 2006 Aug;20(8):1894-911
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The expression of human (h) calcitonin (CT) and its receptor (CTR) is localized to basal epithelium in benign prostates but is distributed in whole epithelium of malignant prostates.
  • Moreover, the abundance of hCT and CTR mRNA in primary prostate tumors positively correlates with the tumor grade.
  • These results, when combined with our other results, that the expression of hCT in primary PCs increase with tumor grade, suggest an important role for hCT in the progression of PC to a metastatic phenotype.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. Calcitonin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16574742.001).
  • [ISSN] 0888-8809
  • [Journal-full-title] Molecular endocrinology (Baltimore, Md.)
  • [ISO-abbreviation] Mol. Endocrinol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA096534; United States / NCI NIH HHS / CA / CA96534
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / PLAUR protein, human; 0 / Plaur protein, mouse; 0 / RNA, Messenger; 0 / Receptors, Cell Surface; 0 / Receptors, Urokinase Plasminogen Activator; 9007-12-9 / Calcitonin; EC 2.7.11.11 / Cyclic AMP-Dependent Protein Kinases; EC 3.4.21.73 / Urokinase-Type Plasminogen Activator
  •  go-up   go-down


96. Van Effenterre R, Boch AL: [Craniopharyngiomas]. Ann Endocrinol (Paris); 2007 Dec;68(6):412-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Craniopharyngiomas are rare benign epithelial tumors, arising from the pituitary stalk or gland and developing in the sellar and suprasellar region, affecting both adults and children.
  • Diagnosis is made on MRI and CT scan, demonstrating a sellar or suprasellar tumor, heterogeneous, with frequent calcifications.
  • This classification allows surgical series comparison, which is of importance since developments and extensions of the tumor can explain surgical difficulties.
  • Because it is an extra-cerebral benign lesion, the ideal goal of treatment should be complete tumor removal with improvement of altered visual functions, minimal deterioration of endocrine function, and no neuropsychological impairment.
  • But the situation of the tumor, its relationship with third ventricle, hypothalamus, optic tract, vascular structures make its removal often difficult.

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17825241.001).
  • [ISSN] 0003-4266
  • [Journal-full-title] Annales d'endocrinologie
  • [ISO-abbreviation] Ann. Endocrinol. (Paris)
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 23
  •  go-up   go-down


97. Ricke WA, Ishii K, Ricke EA, Simko J, Wang Y, Hayward SW, Cunha GR: Steroid hormones stimulate human prostate cancer progression and metastasis. Int J Cancer; 2006 May 1;118(9):2123-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tissue recombinants (TRs) composed of mouse urogenital mesenchyme (mUGM) plus an immortalized nontumorigenic human prostatic epithelial cell line (BPH-1) were grown under the kidney capsule of male athymic nude mice under different hormonal conditions.
  • The objectives were to determine temporal plasma concentrations of testosterone (T) and estradiol-17beta (E2) that elicit progression of nontumorigenic human prostatic epithelial cells in vivo.
  • Untreated mUGM+BPH-1 TRs contained a well organized differentiated epithelium surrounded by smooth muscle stroma similar to developing prostate.
  • In [T+E2]-implanted mice, mUGM+BPH-1 TRs formed carcinomas that contained a fibrous connective tissue stroma permeating the tumor; smooth muscle when present was associated with vasculature.
  • Epithelial cells isolated from untreated mUGM+BPH-1 TRs exhibited benign histology and formed small nontumorigenic grafts when subsequently transplanted into athymic nude mice.
  • In contrast, epithelial cells isolated from mUGM+BPH-1 tumors of [T+E2]-treated hosts formed large tumors that grew independent of stromal and hormonal support and developed lymph node metastases.
  • [MeSH-minor] Animals. Cell Proliferation. Disease Models, Animal. Disease Progression. Epithelial Cells / physiology. Humans. Male. Mesoderm. Mice. Mice, Nude. Neoplasm Metastasis. Prostate / cytology. Transplantation, Heterologous

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ESTRADIOL .
  • Hazardous Substances Data Bank. TESTOSTERONE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2005 Wiley-Liss, Inc.
  • (PMID = 16331600.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Grant] United States / NIA NIH HHS / AG / AG0026604; United States / NCI NIH HHS / CA / CA84294; United States / NCI NIH HHS / CA / CA89520; United States / NCI NIH HHS / CA / CA96403; United States / NCI NIH HHS / CA / CA97725-01; United States / NICHD NIH HHS / HD / HD007263; United States / NCI NIH HHS / CN / N01CN15114-MAO; United States / NCI NIH HHS / CA / U01 CA96403
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 3XMK78S47O / Testosterone; 4TI98Z838E / Estradiol
  •  go-up   go-down


98. Hammes LS, Tekmal RR, Naud P, Edelweiss MI, Kirma N, Valente PT, Syrjänen KJ, Cunha-Filho JS: Up-regulation of VEGF, c-fms and COX-2 expression correlates with severity of cervical cancer precursor (CIN) lesions and invasive disease. Gynecol Oncol; 2008 Sep;110(3):445-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: In this study, 26 cases of benign cervix, 28 low-grade cervical intraepithelial neoplasia (CIN; CIN 1), 30 high-grade CIN (CIN 2/3) and 28 squamous cervical carcinomas (SCC) were examined by immunohistochemistry (IHC) and analysis was performed separately for epithelium and stroma.
  • RESULTS: Positive epithelial expressions in normal cervix, low-grade CIN, high-grade CIN and SCC were, respectively: VEGF - 11.5%, 39.3%, 53.3% and 75% (P<0.001); c-fms - 0%, 10.7%, 40% and 67.9% (P<0.001); COX-2 - 7.7%, 39.3%, 80% and 100% (P<0.001).
  • Stromal VEGF expression was higher than epithelial expression in all CIN grades and was also associated with the lesion grade, while c-fms and COX-2 stromal expression was weak.
  • [MeSH-minor] Female. Humans. Immunohistochemistry. Neoplasm Invasiveness. Neoplasm Staging. Neovascularization, Pathologic / genetics. Neovascularization, Pathologic / metabolism. Neovascularization, Pathologic / pathology. Up-Regulation


99. Noske A, Faggad A, Wirtz R, Darb-Esfahani S, Sehouli J, Sinn B, Nielsen FC, Weichert W, Buckendahl AC, Röske A, Müller B, Dietel M, Denkert C: IMP3 expression in human ovarian cancer is associated with improved survival. Int J Gynecol Pathol; 2009 May;28(3):203-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In contrast, epithelium of borderline tumors, as well as, benign ovarian lesions and normal ovaries exhibited only weak or no IMP3 expression.
  • [MeSH-major] Biomarkers, Tumor / analysis. Neoplasm Proteins / biosynthesis. Ovarian Neoplasms / pathology. RNA-Binding Proteins / biosynthesis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Blotting, Western. Female. Gene Expression. Humans. Kaplan-Meier Estimate. Middle Aged. Neoplasm Staging. Prognosis. RNA, Messenger / analysis. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19620937.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / IMP3 protein, human; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / RNA-Binding Proteins
  •  go-up   go-down


100. Yi N, Liao QP, Li T, Xiong Y: Novel expression profiles and invasiveness-related biology function of DKK1 in endometrial carcinoma. Oncol Rep; 2009 Jun;21(6):1421-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Previous studies in some malignant tumors revealed the possibility that DKK1 is involved in tumorigenesis inducing abnormalities of the Wnt signal pathway.
  • In this study, we showed that in benign and malignant endometrium, DKK1 exhibited novel expression profiles and invasiveness-related biology function: DKK1 was expressed in both glandular epithelium and matrix of two kinds of endometrium tissues and mostly distributed in the cytoplasm and epicytes of endometrial carcinoma (EC) Ishikawa cell line.
  • DKK1 expression level in EC was significantly lower than that in benign endometrium.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / metabolism. Carcinoma / metabolism. Endometrial Neoplasms / metabolism. Endometrium / metabolism. Intercellular Signaling Peptides and Proteins / metabolism
  • [MeSH-minor] Adult. Aged. Cell Line, Tumor. Cell Movement. Down-Regulation. Female. Humans. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Signal Transduction. beta Catenin / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19424619.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CTNNB1 protein, human; 0 / DKK1 protein, human; 0 / Intercellular Signaling Peptides and Proteins; 0 / beta Catenin
  •  go-up   go-down






Advertisement